Cancer Guidelines Database

This is a clinical practice guideline for patients with bladder cancer. The guideline provides recommendations for the post-treatment surveillance of these patients, using various radiological imaging modalities. Several techniques employing ultrasound (US), magnetic resonance imaging (MRI), and computed tomography (CT) are discussed.

This is a clinical practice guideline for patients with peritoneal surface malignancies. Recommendations are provided on the use of cytoreductive surgery with or without the addition of hyperthermic intra-peritoneal chemotherapy, for the treatment of these patients. Part two of a two-part series, this guideline specifically discusses post-operative management. Outcomes of interest include length of stay, complications, and mortality rate.

This is a clinical practice guideline for patients with prostate cancer. The guideline examines the diagnosis, classification and staging, treatment, and follow-up of these patients. Quality of life outcomes are also discussed. This is a web-based guideline and may be updated as new evidence arises - this review pertains to the guideline as of February 12, 2021.

This is a clinical practice guideline for patients with non-muscle-invasive bladder cancer. The guideline examines the diagnosis, staging and classification, management and follow-up of these patients. Predicting disease recurrence and progression is also discussed. This is a web-based guideline and may be updated as new evidence arises - this review pertains to the guideline as of February 12, 2021.

This is a clinical practice guideline for adults with suspected or confirmed upper urinary tract urothelial cell carcinoma. The guideline provides recommendations on the diagnosis, staging and classification, prognosis, treatment, and follow-up of these patients. This a web-based guideline and may be updated as new evidence arises - this review pertains to the guideline as of February 10th, 2021.

This is a clinical practice guideline for adults with suspected or confirmed muscle-invasive or metastatic bladder cancer. Recommendations are provided for the diagnosis, staging and classification, treatment, and follow-up of these patients. This a web-based guideline and may be updated as new evidence arises - this review pertains to the guideline as of February 10th, 2021.

This is a clinical practice guideline for patients with suspected or confirmed primary urethral carcinoma. Recommendations are provided for the diagnosis, staging and classification, treatment, and follow-up of these patients. This a web-based guideline and may be updated as new evidence arises - this review pertains to the guideline as of February 10th, 2021.

This is a clinical practice guideline for adults with suspected or confirmed renal cell carcinoma. The guideline provides recommendations on the diagnosis, staging and classification, prognosis, treatment, and follow-up of these patients. This a web-based guideline and may be updated as new evidence arises - this review pertains to the guideline as of February 24th, 2021.

This is a clinical practice guideline for adults with suspected or confirmed testicular cancer. Recommendations are provided for the diagnosis, staging and classification, treatment, and follow-up of these patients. This a web-based guideline and may be updated as new evidence arises - this review pertains to the guideline as of February 25th, 2021.

This is a clinical practice guideline for men with suspected or recently diagnosed localized prostate cancer. The guideline provides recommendations for the staging and treatment of these patients, with treatment options stratified based on whether patients have low-risk, intermediate-risk, or high-risk disease. Several treatment approaches are discussed, including active surveillance, radical prostatectomy, low dose rate (LDR) brachytherapy, external beam radiotherapy, whole gland cryosurgery, and whole gland high intensity focused ultrasound (HIFU).

This is a clinical practice guideline for adults with rectal cancer. The guideline provides recommendations for the staging and treatment of these patients. Specific topics discussed include preoperative assessment, multidisciplinary treatment planning, and responding to tumour-related emergencies.

This is a clinical practice guideline for female survivors of childhood, adolescent, and young adult (CAYA) cancer. The guideline examines breast cancer surveillance in these patients, including patient selection, when it should be initiated, at what frequency it should be performed, and what surveillance modality should be used. Outcomes of interest include improved life expectancy and quality of life, as well as decreased morbidity related to the avoidance of new cancer treatment.

This is a clinical practice guideline for childhood, adolescent, and young adult cancer survivors. The guideline examines the surveillance of cancer-related fatigue in these patients. Patient selection for surveillance, the age or time from exposure at which surveillance should be performed, the frequency of surveillance, and appropriate surveillance modalities are specifically discussed.

This is a clinical practice guideline for women who have been diagnosed with vulvar cancer. The guideline provides recommendations on radiological imaging in these patients, for the purposes of pre-treatment staging and post-treatment follow-up. Magnetic resonance imaging (MRI), ultrasound (US), computed tomography (CT), and lymphoscintigraphy are specific imaging modalities discussed.

This is a clinical practice guideline for patients with gastric cancer. The guideline examines the pathology, initial workup, staging, treatment, follow-up, and supportive care of these patients. Treatment options discussed include lymph node dissection, laparoscopic resection, endoscopy, radiation therapy, combined modality therapy, chemotherapy (preoperative, perioperative, and postoperative), and targeted therapies.

This is a clinical practice guideline for patients with small bowel adenocarcinoma. The guideline discusses the clinical presentation and workup, pathology, staging, and treatment of these patients. Treatment options are specifically addressed for stage I-III and distant metastatic (stage IV) small bowel adenocarcinomas. Risk factors, post-treatment surveillance and survivorship are also examined.

This is a clinical practice guideline for patients living with HIV (PLWH) who are diagnosed with cancer. The guideline focuses primarily on PLWH who develop non-small cell lung cancer (NSCLC), anal cancer, Hodgkin lymphoma, or cervical cancer. General advice is also provided regarding HIV management during cancer therapy, in addition to topics such as drug-drug interactions (DDI) between antiretroviral treatments and cancer therapies, initial workup, radiation therapy, surgical management, and supportive care.

This is a clinical practice guideline for adolescents and young adults with cancer. The guideline discusses risk factors, screening, diagnosis, management, follow-up, supportive care, and palliative care for patients between 15 and 39 years of age. Unique issues discussed include adherence to treatment, the impact of cancer and its treatment on fertility, management of cancer during pregnancy, relationship management, and socioeconomic issues.

This is a clinical practice guideline for patients aged 15-39 years who have been diagnosed with cancer. The guideline discusses screening and assessment strategies, access and participation in clinical trials, as well as approaches to treatment in this patient population. Additional topics addressed include the facilitation of psychosocial care, survivorship care planning, and the optimization of palliative care.

This is a clinical practice guideline for survivors of childhood, adolescent and young adult (CAYA) cancers. The guideline examines differentiated thyroid surveillance strategies and modalities in these patients. Outcomes of interest include morbidity, disease recurrence, and mortality.

This is a clinical practice guideline for older adults (i.e., ≥ 55 years of age) with newly diagnosed acute myeloid leukemia (AML). The guideline provides recommendations for the management of these patients throughout the cancer care continuum. Specific topics discussed include post-remission therapy, and considerations for end-of-life and/or hospice care.

This is a clinical practice guideline for adults with non-muscle invasive bladder cancer (NMIBC). The guideline provides recommendations for the diagnosis, staging, treatment, and follow-up of these patients. Specific topics discussed include risk stratification, the use of urine markers after diagnosis, transurethral resection of bladder tumour (TURBT), intravesical therapy, relapse and salvage regimens, as well as enhanced cystoscopy.

This is a clinical practice guideline for patients with colorectal cancer. The guideline examines clinical indications for the use of imaging alternatives to standard colonoscopy in these patients, including computed tomographic colonography (CTC) and colon capsule endoscopy (CCE). Radiological imaging for the diagnosis of colorectal neoplasia, completion of a previously incomplete colonoscopy, indications and contraindications to CTC/CCE following positive fecal occult blood test or fecal immunochemical test, and post-polypectomy surveillance are specifically discussed, as are indications and contraindications for CTC, the latter of which including diverticular disease, inflammatory bowel disease, and patient fragility.

This is a clinical practice guideline for the surveillance of patients who have undergone polypectomy. The quality of baseline colonoscopy, polyp size evaluation, appropriate scheduling of colonoscopy surveillance, patient selection for surveillance, timing of second surveillance colonoscopy, piecemeal resection, and ending post-polypectomy surveillance are specifically discussed. The primary outcomes of interest are colorectal cancer incidence and mortality.

This is a clinical practice guideline for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma. The guideline examines consolidation or maintenance systemic therapy for the treatment of these patients, after receiving first-line therapy with cytoreductive surgery and adjuvant therapy. Outcomes of interest include overall survival and progression-free survival.

This is a clinical practice guideline for patients with metastatic pancreatic adenocarcinoma. The guideline examines therapy options after first-line treatment in these patients. Specific topics of interest include initial patient assessment, palliative care, treatment of pain and/or symptoms, as well as follow-up and surveillance strategies.

This is a clinical practice guideline for adults with ovarian cancer. The guideline specifically examines the use of poly (ADP-ribose) polymerase inhibitors, or PARPis, for the management of epithelial ovarian, tubal, or primary peritoneal cancer. The management of newly diagnosed versus recurrent ovarian cancer, and the management of adverse events are discussed. Outcomes of interest include therapeutic efficacy (e.g., survival, response rate) and health-related quality of life.

This is a clinical practice guideline for patients with suspected or confirmed follicular lymphoma (FL). The guideline provides recommendations on the diagnosis and treatment of these patients. Specific topics of interest include prognostic factors in FL, the management of patients with newly diagnosed versus recurrent FL, and experimental treatments. Progression-free survival and overall survival are the primary outcomes of interest.

This is a clinical practice guideline for adults with suspected or confirmed esophageal cancer, and specifically for those with epithelial cancer originating in the esophagus. The guideline provides recommendations for the diagnosis, staging, treatment and follow-up of these patients, with treatment guidelines based on disease type and stage. Specific topics discussed include the diagnostic differentiation between T1a‑EP/LPM and T1a‑MM disease, the selection of lesions for endoscopic treatment, the prevention of post-endoscopy stenosis, as well the relative appropriateness of surgery or definitive chemoradiotherapy.

This is a clinical practice guideline for patients with central nervous system cancers. The guideline examines the diagnosis, staging, treatment, and follow-up of these patients. Surgical options, adjuvant therapy, and postoperative staging are specifically considered.

This is a clinical practice guideline for patients with chronic myeloid leukemia (CML). The guideline discusses diagnosis and workup, staging, and management options for these patients, and includes specific considerations for children with CML. The guideline separates treatment options based on characteristics such as genetic profile, and phase (i.e. chronic phase, accelerated phase, and blast phase). Topics discussed include toxicities and response milestones for different treatment options.

This is a clinical practice guideline for adults with esophageal or esophagogastric junction cancer. The guideline specifically examines the initial workup, histological staging, primary treatment, and follow-up of both squamous cell carcinoma and adenocarcinoma. Treatment modalities discussed include surgery, radiation therapy, combined modality therapy, chemotherapy, and targeted therapies.

This is a clinical practice guideline for adult cancer patients who are receiving immunotherapy as part of their treatment. The guideline provides recommendations for the management of immune-related adverse events (irAEs) in these patients. Immunotherapy agents discussed include atezolizumab, ipilimumab, nivolumab, pembrolizumab, avelumab, durvalumab, and cemiplimab.

This is a clinical practice guideline for patients with chronic myeloid leukemia. The guideline examines diagnosis and baseline investigations of suspected or confirmed chronic myeloid leukemia, recommended treatment options, and monitoring criteria. Outcomes of interest include risk of disease progression and survival.

This is a clinical practice guideline for patients with diagnosed or suspected advanced/metastatic prostate cancer. The guideline examines the appropriate staging, treatment and follow-up for this patient population. Management, monitoring, systemic therapy, and radiotherapy are also discussed.

This is a clinical practice guideline for patients who have been diagnosed with or who are at high risk for hepatocellular carcinoma (HCC). The guideline provides recommendation for the primary, secondary, or tertiary prevention of HCC, the surveillance of patients who are at high risk for developing HCC, the diagnosis and staging of HCC, as well as the treatment and follow-up of patients with HCC. Surgery and radiation therapy are the primary treatment modalities discussed.

This is a clinical practice guideline for the diagnosis and treatment of anal intraepithelial neoplasia (AIN). Diagnostic elements discussed include clinical evaluation with associated digital rectal examination (DARE), as well as brushing and viral typing, anoscopy, and biopsy. For the treatment of AIN, the guideline examines topical treatments such as imiquimod, 5-fluorouracil (5-FU), cidofovir and trichloroacetic acid (TCA), as well as ablative methods, including electrocautery, radiofrequency ablation (RFA), CO2 laser therapy, infrared coagulation (IRC), photodynamic therapy and surgery. The primary outcome of interest is the prevention of squamous cell carcinoma (SCC).

This is a clinical practice guideline for patients with Hodgkin and non-Hodgkin lymphoma, who have undergone autologous hematopoietic cell transplantation (auto-HCT). The guideline examines the use of various maintenance therapies used to mitigate disease relapse in these patients. In additional to disease recurrence, outcomes of interest include progression-free and overall survival.

This is a clinical practice guideline for adult cancer patients who are at risk for developing chemotherapy-induced neutropenia and sepsis. The guideline examines the management of sepsis and septic shock in these patients, as compared to non-neutropenic patients. Topics of interest include risk factors associated with neutropenic sepsis, screening criteria for sepsis, and various treatment strategies.

This is a clinical practice guideline for adult patients with suspected or confirmed colorectal carcinoma. Recommendations are provided for the diagnosis and treatment of these patients. Specific topics addressed include preoperative local staging, local ablation methods, and the diagnosis of distant metastases.

This is a clinical practice guideline for adult patients who are undergoing liver transplantation, and is specifically targeted towards Asian patients. The guideline provides recommendations for the immunosuppression of these patients, and includes a discussion of several immunosuppressants. Specific topics addressed include the effects of various agents on renal toxicity, hepatocellular carcinoma recurrence, and the impact of non-adherence to immunosuppressive therapy.

This is a clinical practice guideline for adult cancer survivors and those living with advanced disease. The guideline examines the screening, diagnosis and management of cancer-related pain in these patients. Specific topics addressed include the frequency of pain screening, support for patient self-management, as well as patient-specific, multimodal treatment plans.

This is a clinical practice guideline for women who have been diagnosed with uterine cervical cancer. The guideline discusses the treatment of these patients, and recommendations are separated based on disease type/stage. Specific topics examined include the primary treatment for cervical precancerous lesions and IA cervical cancer, the primary treatment for stage IB-II cervical cancer, postoperative therapy for stage IB–II cervical cancer, the primary therapy for stage III-IV cervical cancer, therapies for relapsed cervical cancer, and the management of cervical cancer during pregnancy.

This is a clinical practice guideline for adult cancer survivors with, or at risk for developing, chemotherapy-induced peripheral neuropathy (CIPN). The guideline examines prevention and treatment approaches in the management of chemotherapy-induced neuropathies. Various agents and interventions are assessed in the prevention of CIPN. Treatment recommendations are divided between patients who are receiving neurotoxic chemotherapy and patients who have completed neurotoxic chemotherapy.

This is a clinical practice guideline for women with Stage I breast cancer. The guideline examines the appropriateness of various imaging techniques during the management of these patients. Specific clinical situations addressed include the initial imaging of asymptomatic patients to exclude bone, thoracic, abdominal, and brain metastases, as well as surveillance imaging for the purposes of ruling out local recurrence.

This is a clinical practice guideline for women who have been diagnosed with endometrial cancer. The guideline examines the appropriateness of various imaging techniques during the pre-treatment evaluation and follow-up of these patients. Specific situations discussed include the initial staging of endometrial cancer, the surveillance of asymptomatic patients with treated low- or intermediate-risk endometrial cancer, as well as the post-therapy evaluation of clinically suspected recurrence of known endometrial cancer.

This is a clinical practice guideline for patients with localized renal cell cancer. The guideline examines follow-up and active surveillance strategies for patients with treated or untreated disease. The appropriateness of various radiologic imaging procedures is evaluated, including magnetic resonance imaging (MRI), computerized tomography (CT), and ultrasound.

This is a clinical practice guideline for patients with bladder cancer. The guideline examines the appropriateness of various post-treatment surveillance procedures, including computerized tomography (CT), magnetic resonance imaging (MRI), ultrasounds, fluoroscopies, and radiographies. Outcomes of interest include disease recurrence and progression.

This is a clinical practice guideline for patients with AIDS-related Kaposi sarcoma. The guideline examines diagnosis, staging, treatment, and follow-up, while also providing recommendations on HIV screening and HIV therapy during cancer treatment. Antiretroviral therapy (ART), topical therapies, intralesional chemotherapy, local incisions, radiation therapy, and systemic therapy are all discussed as treatment options.

This is a clinical practice guideline for patients with bladder cancer. Non-muscle-invasive urothelial bladder cancer, muscle-invasive urothelial bladder cancer, metastatic (Stage IVB) urothelial bladder cancer, non-urothelial carcinomas of the bladder, upper tract urothelial carcinoma (UTUC), urothelial carcinomas of the prostate, and primary carcinomas of the urethra are all specifically discussed. The guideline provides algorithms for diagnosis, staging, treatment, and follow-up.

This is a clinical practice guideline for patients with head and neck cancers. The guideline examines workup and staging, treatment, and follow-up for various head and neck cancers including cancer of the lip, oral cavity, oropharynx, hypopharynx, nasopharynx, and larynx, as well as paranasal tumours, very advanced head and neck cancers, occult primary cancer, salivary gland tumours, and mucosal melanoma of the head and neck. Nutrition, supportive care, comorbidities, quality of life, and dental evaluation and management are also discussed.

This is a clinical practice guideline for hepatobiliary cancers. The guideline examines the clinical management of patients with hepatocellular carcinoma (HCC), gallbladder cancer, as well as intrahepatic and extrahepatic cholangiocarcinoma. Risk factors, diagnosis, staging and prognosis, and treatment are discussed for the different conditions.

This is a clinical practice guideline for patients with neuroendocrine or adrenal tumours. The guideline discusses the diagnosis, staging, treatment, and follow-up of patients with sporadic neuroendocrine tumours, originating from organs such as the lungs, thymus, and gastrointestinal (GI) tract. The guideline also examines the role of the genetic syndrome, multiple endocrine neoplasia (MEN), in developing parathyroid, pituitary, and pancreatic tumours.

This is a clinical practice guideline for the management of squamous cell carcinoma (SCC) of the penis. The guideline examines the diagnosis, treatment, and follow-up for patients with this form of cancer. Outcomes of interest include optimizing therapeutic efficacy and minimizing treatment-related morbidity.

This is a clinical practice guideline for the management of rectal cancer. The guideline provides recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, management of recurrent and metastatic disease, and patient surveillance. Outcomes of interest include safety and efficacy of treatment, adverse outcomes, and overall survival.

This is a clinical practice guideline for patients with suspected or confirmed esophageal cancer. The guideline examines the diagnosis, staging, and treatment of these patients, and includes a discussion of multiple treatment modalities. Outcomes of interest include morbidity, local recurrence, and survival.

This is a clinical practice guideline for patients with hepatitis C virus (HCV) infection who have received direct-acting antiviral (DAA) medication. The guideline provides recommendations on the follow-up these patients for the purposes of reducing the incidences of hepatocellular carcinoma (HCC), as well as hepatitis B virus (HBV) reactivation in those who are co-infected with HBV and HCV. Surveillance intervals and monitoring techniques are specifically discussed, with recommendations separated based on whether patients have a history of HCC.

This is a clinical practice guideline for patients with suspected or confirmed adenocarcinoma in situ (AIS) of the uterine cervix. Recommendations are provided for the diagnosis, treatment, and follow-up of these patients. The guideline discusses excisional treatment under colposcopic guidance, treatment for women who desire to preserve fertility, hysterectomy, and more.

This is a clinical practice guideline for childhood, adolescent, and young adult (CAYA) cancer survivors. The guideline aims to improve the quality of care for this patient population by providing recommendations on the implementation of long-term follow-up (LTFU) care. The organization of LTFU care, personnel involved in LTFU care, components of LTFU care and the appropriate start of LTFU care are all discussed.

This is a clinical practice guideline for patients with basal cell carcinoma (BCC). The guideline examines the diagnosis, treatment and follow-up of these patients. Treatment options discussed include surgical therapy, topical therapies, destructive therapies, photodynamic therapy, combined therapies, medical therapy and radiotherapy, and options are stratified by a proposed disease classification system that is based on the difficulty of successful treatment.

This is a clinical practice guideline for adults with suspected or confirmed Merkel cell carcinoma (MCC). The guideline discusses the main techniques used for initial diagnosis and staging of MCC, as well as treatment options available for localized MCC. Specific topics addressed include the appropriateness of the AEIOU acronym (Asymptomatic, Expanding Rapidly, Immune suppression, Older than 50 years, UV-exposed site) for diagnosis, and the use of sentinel lymph node (SLN) biopsy during treatment.

This is a clinical practice guideline for adults with hepatocellular carcinoma (HCC), with specific recommendations for patients with very early stage, early stage, intermediate stage, advanced stage, and terminal stage HCC. The guideline examines the diagnostic work-up, management, and follow-up of these patients. For each HCC stage, the patient requirements, tumour requirements, goals of treatment, and specific management options are discussed.

This is a clinical practice guideline for adults with a diagnosis of non-metastatic, muscle-invasive bladder cancer, including patients with a single regional lymph node metastasis in the true pelvis. The guideline examines the staging, treatment, and follow-up of these patients. Neoadjuvant chemotherapy, radical cystectomy with bilateral pelvic lymph node dissection, bladder preservation / combined modality approaches, adjuvant chemotherapy, and adjuvant radiotherapy are all discussed as management options. The guideline also addresses special situations, including small cell carcinoma of the bladder, urachal adenocarcinomas, and non-urothelial histology.

This is a clinical practice guideline for adult men with a suspicion or recent diagnosis of localized prostate cancer. The guideline provides recommendations for the staging, management, and follow-up of these patients. Different management options are provided for patients with low-risk, intermediate-risk, or high-risk disease, and include active surveillance, radiotherapy, and surgery.

This is a clinical practice guideline for adults with a diagnosis, or suspected diagnosis of renal cell carcinoma (RCC). The guideline examines the appropriate diagnostic tests for RCC, as well as management and follow-up strategies for those who are diagnosed. Surgical options, systemic therapy and radiotherapy are specifically discussed.

This is a clinical practice guideline for patients with gastric intestinal metaplasia (GIM) detected as part of routine upper endoscopy. The guideline examines the management of these patients, including the testing and treating of Helicobacter pylori infections, as well as subsequent surveillance using upper endoscopy. Outcomes of interest include early gastric cancer detection, reduced morbidity and mortality from gastric cancer, complications associated with endoscopy, and psychological outcomes.

This is a clinical practice guideline for adults who have undergone a colonoscopy with or without polypectomy. The guideline provides risk-stratified recommendations for the follow-up of these patients. Risk categories are based on initial colonoscopy findings, including the presence of adenomas, sessile serrated adenomas/polyps or sessile serrated polyps (SSP), hyperplastic polyps (HP), traditional serrated adenomas (TSA), or colorectal cancer (CRC).

This is a clinical practice guideline for adult patients with chronic radiation proctopathy resulting from radiation therapy received for the treatment of pelvic neoplasms. The guideline provides recommendations on endoscopic therapy in these patients to manage bleeding. Specific endoscopic modalities discussed include argon plasma coagulation (APC), bipolar electrocoagulation, heater probe, radiofrequency ablation (RFA), and cryoablation.

This clinical practice guideline is an endorsement of the National Institute for Health and Care Excellence and the Society for Immunotherapy of Cancer's guidelines for the treatment of patients with non-small cell lung cancer (NSCLC). The guideline specifically examines different treatment options for patients with clinical stage III N2 NSCLC. Primary outcomes of interest include overall survival and quality of life.

This is a clinical practice guideline for patients with bladder cancer. Non-muscle-invasive urothelial bladder cancer, muscle-invasive urothelial bladder cancer, metastatic (Stage IVB) urothelial bladder cancer, non-urothelial carcinomas of the bladder, upper tract urothelial carcinoma (UTUC), urothelial carcinomas of the prostate, and primary carcinomas of the urethra are all specifically discussed. The guideline provides algorithms for diagnosis, staging, treatment, and follow-up.

This is a clinical practice guideline for patients with chronic myeloid leukemia (CML). The guideline discusses diagnosis and workup, staging, and management options for these patients, and includes specific considerations for children with CML. The guideline separates treatment options based on characteristics such as genetic profile, and phase (i.e. chronic phase, accelerated phase, and blast phase). Topics discussed include toxicities and response milestones for different treatment options.

This is a clinical practice guideline for adults with classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). The guideline discusses the clinical management of patients with CHL and NLPHL, focusing on patients who do not have serious intercurrent disease. Treatment options examined include chemotherapy, high dose therapy and autologous stem cell rescue (HDT/ASCR), and involved site radiation therapy (ISRT).

This is a clinical practice guideline for patients with Waldenström macroglobulinemia or lymphoplasmacytic lymphoma. The guideline examines the diagnosis, workup, primary treatment regimens, assessment of response to primary treatment, and follow-up after primary treatment. Regimens not toxic to stem cells and regimens with potential or unknown toxicity to stem cells are considered. Treatment of Immunoglobulin M (IgM) related peripheral neuropathy, maintenance therapy, and therapy for previously treated Waldenström macroglobulinemia are also discussed.

This is a clinical practice guideline for children and young adults with aggressive mature B-cell lymphomas, including Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). The guideline discusses the pathology and diagnosis, staging, initial treatment, disease reassessment, surveillance, therapy for relapsed/refractory disease, and supportive care for these patients. Specific recommendations are provided based on disease type and stage.

A clinical practice guideline on the diagnosis, workup, and treatment of patients who have been diagnosed with or are suspected of having primary cutaneous B-cell lymphomas (PCBCLs). The guideline focuses on the three main types of PCBCLs: primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle-center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, leg type). Recommendations for treatment are provided based on lymphoma type and whether treatment is for initial, relapsed, or refractory disease.

This is a clinical practice guideline for patients with testicular germ cell tumours (GCTs). The guideline examines the clinical presentation, workup, primary treatment, and pathologic diagnoses of these patients. Separate recommendations are provided for different stages of pure seminomas and nonseminomas, and the guideline also discusses second-line and subsequent therapies for metastatic GCTs.

This is a clinical practice guideline for adults and children experiencing cancer-related fatigue (CRF). The guideline discusses screening for CRF, as well as evaluation approaches using focused history, assessment of treatable contributing factors, and patient clinical status. General strategies for managing CRF are discussed, and the guideline examines pharmacological and non-pharmacological treatments for patients based on their placement within the care continuum (i.e. active treatment, post-treatment, and end-of-life).

This is a clinical practice guideline for adult cancer patients who have received or are being considered for hematopoietic cell transplantation (HCT), including autologous or allogenic HCT. The guideline discusses pre-transplant recipient evaluation, as well as the management of acute and chronic graft-versus-host disease (GVHD) in these patients. Specific recommendations are provided pertaining to the diagnosis and staging, first line treatment, and additional therapy for GVHD.

This is a clinical practice guideline for adult patients with advanced cancer who are experiencing loss of appetite, body weight, and/or lean body mass (i.e. skeletal muscle). The guideline examines nutritional, pharmacologic, and other (e.g. exercise) interventions for managing these patients. Outcomes of interest include body weight, lean body mass, appetite, physical function, and quality of life.

This is a clinical practice guideline for adults with squamous cell carcinoma arising within the anal canal. The guideline provides recommendations for the diagnosis and staging of these patients, as well as specific treatment recommendations based on disease stage. Specific topics addressed include the treatment of patients who have undergone curative therapy, those with locally recurrent cancer, and those with metastatic cancer.

This is a clinical practice guideline for adults with esophageal cancer, including both squamous cell esophageal cancer and adenocarcinoma. The guideline provides recommendations for the diagnosis and staging of these patients, as well as treatment options based on disease stage. The treatment of potentially curable esophageal cancer, as well as palliative approaches to incurable esophageal cancer, are specifically discussed.

This is a clinical practice guideline for adults who have been diagnosed with locally advanced/metastatic bladder cancer (i.e. T4bNxM0, TxN2-3M0, TxNxM1). The guideline provides recommendations for staging of these patients, as well as treatment and follow-up options based on disease stage. Treatment modalities discussed include surgery, systemic therapy, and radiotherapy. For patients with metastatic cancer, palliative approaches are also discussed.

This is a clinical practice guideline for adult patients who have been diagnosed with or who are at a high risk of developing colorectal cancer (CRC). Topics examined include the prevention of CRC in patients with Lynch syndrome, management of local disease, and management of metastatic disease. Specific recommendations are provided based on disease location (e.g., the rectum or colon).

This is a clinical practice guideline for adults with colorectal cancer who have developed liver metastases. The guideline examines regional therapies for the management of these patients, including conventional transarterial chemoembolization (cTACE), drug-eluting bead transarterial chemoembolization (DEB-TACE), and transarterial radioembolization (TARE). Outcomes of interest include overall survival, progression-free survival, time to progression, time to hepatic progression, overall response rate, and toxicity.

This is a clinical practice guideline for adults with curatively treated stage I-III non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC). The guideline examines radiographic imaging and biomarker surveillance strategies for these patients. The frequency of surveillance imaging, optimal imaging modalities, patient factors that would preclude surveillance, the role of circulating biomarkers in surveillance, and the appropriateness of using magnetic resonance imaging (MRI) for NSCLC and SCLC are all specifically discussed.

This is a clinical practice guideline for patients with acute lymphoblastic leukemia (ALL) who are being treated in a pediatric oncology setting; the guideline focuses on children, however, recommendations may apply to those up to 30 years of age. Recommendations are provided for the diagnosis, workup, treatment, and supportive care of these patients. Specific topics addressed include risk stratification, treatment in vulnerable populations, as well as the evaluation and treatment of extramedullary disease.

This is a clinical practice guideline for patients with bladder cancer. Non-muscle-invasive urothelial bladder cancer, muscle-invasive urothelial bladder cancer, metastatic (Stage IVB) urothelial bladder cancer, non-urothelial carcinomas of the bladder, upper tract urothelial carcinoma (UTUC), urothelial carcinomas of the prostate, and primary carcinomas of the urethra are all specifically discussed. The guideline provides algorithms for diagnosis, staging, treatment, and follow-up.

This is a clinical practice guideline for patients with central nervous system cancers. The guideline examines the diagnosis, staging, treatment, and follow-up of these patients. Surgical options, adjuvant therapy, and postoperative staging are specifically considered.

This is a clinical practice guideline for patients with chronic lymphocytic leukemia, or small lymphocytic lymphoma. The guideline examines the diagnosis, staging, treatment, and follow-up of these patients. Prognosis and treatment algorithms are presented based on patient characteristics such as age, and genetic profile.

This is a clinical practice guideline for patients with testicular germ cell tumours (GCTs). The guideline examines the clinical presentation, workup, primary treatment, and pathologic diagnoses of these patients. Separate recommendations are provided for different stages of pure seminomas and nonseminomas, and the guideline also discusses second-line and subsequent therapies for metastatic GCTs.

This clinical practice guideline is for patients undergoing major abdominal surgery, including patients with cancer. The guideline provides recommendations for preoperative care before procedures such as colorectal surgery, gastrectomy, gastric bypass, hysterectomy, prostatectomy, and cystectomy, as well as other oncological, gynecological, and urological surgeries. Outcomes of interest include the prevention of surgical complications and reductions in hospital stays.

This clinical practice guideline is an endorsement of the American Society of Clinical Oncology’s 2017 guideline titled Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. The guideline discusses the use of antiemetics for the prevention and management of nausea and vomiting in adult patients undergoing chemotherapy and/or radiotherapy. Various treatment regimens are examined based on the frequency of emesis. Other topics of interest include the use of adjunctive drugs, cannabinoids, as well as other complementary and alternative therapies.

This is a clinical practice guideline for men who have been diagnosed with invasive breast cancer. The guideline examines management strategies for these patients. Specific topics discussed include adjuvant endocrine therapy, targeted therapies, management of treatment-related adverse effects, genetic testing, and post-treatment surveillance.

This is a clinical practice guideline for patients undergoing potentially cardiotoxic oncological treatment, including chemotherapy, targeted therapy and radiotherapy. The guideline examines various prevention, detection, treatment and monitoring strategies available for reducing cardiovascular toxicity in these patients. Outcomes of interest include cardiovascular morbidity, and mortality.

This is a clinical practice guideline for adults with appendiceal neoplasms, excluding GI stromal tumours, lymphomas, and neural proliferations. The guideline provides recommendations on the management of these patients. Specific topics discussed include colonoscopy, pre-operative assessment, appendectomy, biochemical testing, and post-operative surveillance. Outcomes of interest include recurrence rate of neoplasms and disease-free survival.

This is a clinical practice guideline for the assessment of patients who are at high risk for colorectal cancer due to genetic or familial factors. The guideline provides recommendations for the management of patients with high-risk syndromes, including Lynch syndrome, familial adenomatous polyposis (FAP), Peutz-Jeghers syndrome (PJS), Juvenile Polyposis Syndrome (JPS), Serrated Polyposis Syndrome (SPS), and other high-risk syndromes associated with colorectal cancer risk.

This is a clinical practice guideline for adult patients with keratinocyte cancer (KC). The guideline examines the prevention, screening, diagnosis, treatment, and follow-up of these patients. Treatment options considered include surgery, radiotherapy, cryotherapy, topical treatments, and photodynamic therapy. Organ transplantation and conditions associated with immunosuppression are also discussed, as are systemic therapies for metastatic disease, the role of primary care, the economics of KC, and common concerns raised by patients. This guideline is wiki-based and is constantly updated as new evidence arises - this review pertains to the guideline as of January 15, 2020.

This is a clinical practice guideline for patients living with HIV (PLWH) who are diagnosed with cancer. The guideline focuses primarily on PLWH who develop non-small cell lung cancer (NSCLC), anal cancer, Hodgkin lymphoma, or cervical cancer. General advice is also provided regarding HIV management during cancer therapy, in addition to topics such as drug-drug interactions (DDI) between antiretroviral treatments and cancer therapies, initial workup, radiation therapy, surgical management, and supportive care.

This is a clinical practice guideline for patients who have undergone hematopoietic stem cell transplantation (HSCT), and/or those who are receiving other types of therapy for hematological malignancies. The guideline examines the prevention, diagnosis, and management of cytomegalovirus (CMV) infection in these patients. The primary outcomes of interest are CMV serostatus and survival.

This is a clinical practice guideline for patients with suspected or confirmed prostate cancer. The guideline provides recommendations for diagnosis, including the use of magnetic resonance imaging (MRI) and biopsy, treatment (i.e. radical treatment), follow-up, and active surveillance using multiparametric MRI.

This is a clinical practice guideline for patients with non-small cell or small cell lung cancer. The guideline provides recommendations on diagnosis, management, follow-up, and palliative care for these patients. Outcomes of interest include length of stay in hospital and intensive care units, quality of life, and overall survival.

This is a clinical practice guideline for hepatobiliary cancers. The guideline examines the clinical management of patients with hepatocellular carcinoma (HCC), gallbladder cancer, as well as intrahepatic and extrahepatic cholangiocarcinoma. Risk factors, diagnosis, staging and prognosis, and treatment are discussed for the different conditions.

This is a clinical practice guideline for patients with myeloproliferative neoplasms. The guideline specifically examines the diagnosis, risk-stratification, treatment, and supportive care for patients with polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF). Risk-stratified treatment algorithms are provided for each disorder.

This is a clinical practice guideline for patients with small cell lung cancer. The guideline examines the diagnosis, staging, prognostic factors, treatment, and surveillance of these patients. Treatment options discussed include systemic therapy, radiotherapy, and surgical resection. Systemic therapy is further examined in elderly patients, and as a second-line (and beyond) treatment. Radiotherapy treatments considered include thoracic radiotherapy, prophylactic cranial irradiation, and palliative radiotherapy.

This is a clinical practice guideline for the management of infusion reactions (IR) caused by cancer medication. The guideline examines prophylaxis, acute management of IRs, as well as re-start and re-challenge protocols. Outcomes of interest include treatment toxicity, adverse events, and the incidence and severity of IRs.

This is an organizational guideline for adult patients with brain metastases who are eligible to receive stereotactic radiosurgery (SRS) in Ontario. Topics of discussion include qualifications for the practice team, the determination of patient eligibility, appropriate technologies for the delivery of SRS, as well as pre- and post-intervention imaging.

This is a clinical practice guideline for adult patients who are receiving treatment for non-metastatic cancer, as well as adult cancer survivors. Recommendations are provided for the management of osteoporosis and osteoporotic fractures in these patients. The guideline specifically discusses which patients are at an increased risk for developing osteoporotic fractures, how these patients should be screened for, which patients should be treated for their osteoporosis, and which interventions should be used (i.e. which interventions are effective at reducing the risk of fracture).

This is a clinical practice guideline for adult patients with chronic lymphocytic leukemia (CLL). The guideline provides recommendations on diagnosis, staging, treatment, follow-up, and supportive care. Patients with newly diagnosed, relapsed, or refractory CLL are all addressed. Outcomes of interest include treatment toxicity, quality of life, progression-free survival, and overall survival.

This is a clinical practice guideline for adult patients with lymphoma, including Hodgkin lymphoma (HL) and non-Hodgkin lymphomas (NHLs). The guideline provides recommendations for staging and re-staging, treatment, as well as follow-up. Outcomes of interest include disease progression, treatment toxicity, quality of life, progression-free survival, and overall survival.

This is a clinical practice guideline for patients with muscle-invasive bladder cancer. The guideline examines the diagnosis, staging, treatment, follow-up, supportive care, and palliative care for these patients. Treatment methods discussed include chemotherapy, surgical management and radiotherapy. Cystectomy pathology, as well as unresectable and oligometastatic disease are also addressed.

This is a clinical practice guideline for adult patients with cancer who are being treated with bone-modifying agents (BMAs). The guideline discusses the prevention and management of medication-related osteonecrosis of the jaw (MRONJ), and specific recommendations are provided for reducing the risk of MRONJ, as well as for the diagnosis and staging of MRONJ. The potential discontinuation of BMA use after a diagnosis of MRONJ, is also addressed.

This is a clinical practice guideline for adult patients who are at an increased risk of developing gastric adenocarcinoma, specifically those with gastric atrophy (GA), gastric intestinal metaplasia (GIM), gastric epithelial dysplasia or early gastric adenocarcinoma limited to the mucosal or superficial submucosal layers. The guideline provides recommendations for the diagnosis and management of these patients, while addressing specific topics such as Helicobacter pylori eradication, endoscopic screening, and endoscopic mucosal resection.

This is a clinical practice guideline for adults who have undergone polypectomy or colorectal cancer resection. The guideline provides a framework on the use of colonoscopy and non-colonoscopic colorectal imaging for the surveillance of these patients. Specific topics addressed include the selection of patients for surveillance, appropriate surveillance intervals, and the timing of surveillance cessation.

This is a clinical practice guideline for men with suspected or confirmed seminoma (clinical stages I, IIA, and IIB) or nonseminomatous germ cell tumours (NSGCTs). The guideline provides recommendations for the diagnosis, staging, treatment selection, and post-treatment surveillance of theses patients. The guideline's primary objective is to limit the burden of therapy and treatment-related toxicity without compromising cancer control. Specific outcomes of interest include treatment-related toxicity, disease recurrence, and survival.

This is a clinical practice guideline for the management of colon cancer. Recommendations are made for diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, and management of recurrence. Principles for the management of metastatic disease are also provided.

This is a clinical practice guideline for adults and children experiencing cancer-related fatigue (CRF). The guideline discusses screening for CRF, as well as evaluation approaches using focused history, assessment of treatable contributing factors, and patient clinical status. General strategies for managing CRF are discussed, and the guideline examines pharmacological and non-pharmacological treatments for patients based on their placement within the care continuum (i.e. active treatment, post-treatment, and end-of-life).

This is a clinical practice guideline on the routine follow-up and surveillance patients with stage I - III non-small cell lung cancer (NSCLC) who have completed treatment (with curative intent), are asymptomatic, and have no physical findings or laboratory abnormalities to suggest metastatic disease. The guideline examines follow-up intervals at years 1, 2, 3 and beyond, the optimal imaging surveillance modalities, recurrence, long-term side effects of curative-intent therapy, and quality of life.

This clinical practice guideline is for the management of squamous cell anal carcinoma. The guideline provides recommendations on staging, treatment, and follow-up. The effectiveness of treatment options such as surgery, chemotherapy, and radiation therapy are compared. Guidance is also provided on dosing regimens, treatment of recurrence, and surveillance following treatment of recurrence.

This is a clinical practice guideline for patients with bladder cancer. Non-muscle-invasive urothelial bladder cancer, muscle-invasive urothelial bladder cancer, metastatic (Stage IVB) urothelial bladder cancer, non-urothelial carcinomas of the bladder, upper tract urothelial carcinoma (UTUC), urothelial carcinomas of the prostate, and primary carcinomas of the urethra are all specifically discussed. The guideline provides algorithms for diagnosis, staging, treatment, and follow-up.

This is a clinical practice guideline for women with cervical cancer. The guideline examines the initial diagnosis and workup, staging, primary and adjuvant treatment, surveillance, and therapy following relapse for these patients. Treatment for metastatic disease is also discussed, as are the topics of incidental cervical cancer and the occurrence of cervical cancer in pregnant women.

This is a clinical practice guideline for patients with chronic lymphocytic leukemia, or small lymphocytic lymphoma. The guideline examines the diagnosis, staging, treatment, and follow-up of these patients. Prognosis and treatment algorithms are presented based on patient characteristics such as age, and genetic profile.

This is a clinical practice guideline for adults with esophageal or esophagogastric junction cancer. The guideline examines the initial workup, histological staging, primary treatment, and follow-up of both squamous cell carcinoma and adenocarcinoma. Treatment modalities discussed include surgery, radiation therapy, combined modality therapy, chemotherapy, and targeted therapies.

This is a clinical practice guideline for patients with gastric cancer. The guideline examines the pathology, initial workup, staging, treatment, follow-up, and supportive care of these patients. Treatment options discussed include lymph node dissection, laparoscopic resection, endoscopy, radiation therapy, combined modality therapy, chemotherapy (preoperative, perioperative, and postoperative), and targeted therapies.

This is a clinical practice guideline for patients with hairy cell leukemia. The guideline provides recommendations regarding diagnosis, initial treatment, response assessment and additional therapy, second-line therapy for relapsed/refractory or progressive disease, and supportive care. The impact of infections, such as hepatitis B (HBV) is also discussed.

This is a clinical practice guideline for patients with head and neck cancers. The guideline examines workup and staging, treatment, and follow-up for various head and neck cancers including cancer of the lip, oral cavity, oropharynx, hypopharynx, nasopharynx, and larynx, as well as paranasal tumours, very advanced head and neck cancers, occult primary cancer, salivary gland tumours, and mucosal melanoma of the head and neck. Nutrition, supportive care, comorbidities, quality of life, and dental evaluation and management are also discussed.

This is a clinical practice guideline for adults with classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). The guideline discusses the clinical management of patients with CHL and NLPHL, focusing on patients who do not have serious intercurrent disease. Treatment options examined include chemotherapy, high dose therapy and autologous stem cell rescue (HDT/ASCR), and involved site radiation therapy (ISRT).

This is a clinical practice guideline for patients with multiple myeloma. The guideline examines the primary therapy and surveillance/follow-up tests for both solitary plasmacytoma and smoldering (asymptomatic) myeloma, and the primary therapy and monitoring for active (symptomatic) myeloma. Stem cell transplants (SCT), including autologous SCT, tandem SCT, and allogeneic SCT, as well as follow-up after stem cell transplants, are also discussed. In addition, the guideline considers diagnostic tests, response criteria, maintenance therapy, treatment of progressive or relapsed myeloma, and supportive care treatment.

A clinical practice guideline on the diagnosis, workup, treatment and surveillance of B-cell lymphoma (BCL) in pediatric and adult patients. The guideline focuses on the most common B-cell lymphomas: follicular lymphoma (FL), marginal zone lymphomas (MZL), nodal MZL, splenic MZL, gastric MALT lymphoma, mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), AIDS-related B-cell lymphoma, post-transplant lymphoproliferative disorders, and Castleman's disease. Additional consideration is paid to the classification systems used in NHL, the role of PET scans in assessment and staging, principles of radiation therapy, and supportive care considerations.

This is a clinical practice guideline for patients with non-small cell lung cancer. The guideline examines the risk factors, classification factors, diagnostic evaluation, pathologic evaluation, staging, predictive and prognostic biomarkers, treatment, and surveillance of lung cancer. Treatment approaches considered include surgery, radiation therapy, and combined modality therapy. The discussion on initial therapy is stratified by disease stage.

This is a clinical practice guideline for patients with epithelial occult primary cancer. The guideline provides recommendations for the evaluation, workup, management, and follow-up of two pathologic diagnoses in patients with epithelial occult primary cancer: adenocarcinoma, or carcinoma not otherwise specified (NOS), and squamous cell carcinoma (SCC). Management options considered include chemotherapy, radiation therapy, locoregional therapeutic options, and specialized approaches, as well as supportive care and management of psychosocial distress.

This is a clinical practice guideline for the management of squamous cell carcinoma (SCC) of the penis. The guideline examines the diagnosis, treatment, and follow-up for patients with this form of cancer. Outcomes of interest include optimizing therapeutic efficacy and minimizing treatment-related morbidity.

This is a clinical practice guideline for patients with small bowel adenocarcinoma. The guideline discusses the clinical presentation and workup, pathology, staging, and treatment of these patients. Treatment options are specifically addressed for stage I-III and distant metastatic (stage IV) small bowel adenocarcinomas. Risk factors, post-treatment surveillance and survivorship are also examined.

This is a clinical practice guideline for patients with thymomas and thymic carcinomas. The guideline examines the diagnosis, staging, and treatment these mediastinal tumours. Surgical resection and radiation therapy are discussed as treatment options.

This is a clinical practice guideline for adults with any type of cancer. The guideline focuses on the screening, assessment, and treatment of cancer-related pain. Specific topics discussed include universal pain screening, management of pain in both opioid-naïve and opioid-tolerant patients, management of opioid-induced adverse effects, procedure-related pain and anxiety, management strategies for specific cancer pain syndromes, adjuvant analgesics for neuropathic pain, psychosocial support, and education for both patients and caregivers.

This is a clinical practice guideline for adult patients with solid tumors or lymphoid blood cancers, and is especially relevant to those receiving chemotherapy. The guideline examines the use of myeloid growth factors (MGFs) for the prevention and management of neutropenia and anemia in these patients. Specific topics addressed include red blood cell transfusion, erythropoietic therapy, as well as iron monitoring and supplementation.

This is a clinical practice guideline for adult patients who have completed treatment for stage I, II, or III colorectal cancer (CRC). The guideline provides recommendations on the post-treatment surveillance of these patients, including the appropriate use and timelines for colonoscopy, computed tomography (CT) scans of the chest, abdomen and pelvis, as well as carcinoembryonic antigen (CEA) protein tests. The guideline also discusses which providers should lead post-treatment surveillance programs.

This is a clinical practice guideline for adult patients with oropharyngeal cancer. The guideline discusses the diagnostic investigations and baseline assessments that should be used for patients with suspected or confirmed oropharyngeal cancer, as well as treatment options for early (stage I and II), locally advanced (stage III and IV), metastatic, and recurrent oropharyngeal cancer. Post-treatment rehabilitation and follow-up strategies are also examined.

This is a clinical practice guideline for patients with acute myeloid leukemia. The guideline examines the diagnosis of these patients, as well as management options including chemotherapy, hematopoietic stem cell transplantation, and palliative approaches. Diagnostic tests and criteria, ancillary tests, definition of CNS status, prognosis/risk stratification, age and cytogenetics are some of the specific aspects of diagnosis addressed.

This is a clinical practice guideline for patients with vulvar and vaginal cancer, including those with epithelial tumours of the vulva or vagina, as well as those with primary vulvar Paget's disease or malignant melanomas of the vulva or vagina. The guideline provides recommendations for the treatment of these patients, and examines specific topics such as primary treatment, management of inguinal lymph nodes, treatment of distant metastases, and treatment of recurrent tumours.

This is a guideline for the prevention, screening/early detection, diagnosis, staging, and management of breast cancer. Management options for early invasive breast cancer, stage I or II tumours, locally advanced breast cancer, inflammatory breast cancer, locoregional recurrence, metastatic breast cancer and special circumstances in breast cancer patients are discussed. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This is a clinical practice guideline for patients who are at risk for developing, or who have been diagnosed with, colon cancer. The guideline examines the screening, diagnosis, treatment and follow-up of this patient population. Treatment options are presented based on the stage of cancer, and include surgical options, surveillance, and much more. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This is a clinical practice guideline for adult patients with neuroendocrine tumours. The guideline examines diagnosis using histological markers and imaging, management of tumours through appropriate treatment strategies, and appropriate time periods for follow-up. Recommendations are presented for both non-pancreatic and pancreatic neuroendocrine tumours. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This is a clinical practice guideline for patients who are at risk for developing, or who have been diagnosed with, rectal cancer. The guideline examines the screening, diagnosis, treatment and follow-up of this patient population. Treatment options are presented based on the stage of cancer, and include surgical options, surveillance, and much more. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This clinical practice guideline provides recommendations for the management of gastric cancer across most components of the cancer care continuum. Topics of discussion include risk factors for stomach cancer, indicated diagnostic tests, staging criteria, recommended treatment options for each stage (including palliative radiation therapy and chemotherapy), and recommended surveillance methods for follow-up. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This is a guideline for the prevention, screening/early detection, diagnosis, staging, and management of endometrial cancer. Management options examined include surgery, adjuvant therapy (e.g. pelvic radiotherapy, chemotherapy), and estrogen replacement therapy. Recommendations for follow-up are presented based on the type of treatment chosen. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This is a clinical practice guideline for patients with gynecological sarcomas. The guideline examines the staging, treatment, and follow-up of these patients. Surgical and adjuvant treatment options are discussed, as is the management of metastatic and recurrent disease. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This clinical practice guideline is focused on the prevention, classification, diagnosis, staging, and management of ovarian epithelial carcinoma. Management options considered include surgery, chemotherapy, radiation therapy (for palliation), and approaches for fertility management. This guideline also discusses hereditary cancer syndromes, tumours of low malignant potential, estrogen replacement therapy, management of serous tubal intraepithelial carcinoma (STIC), and follow-up of patients after treatment. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This clinical practice guideline for patients with suspected or confirmed non-epithelial ovarian cancer. The guideline discusses the prevention, diagnosis, staging, management, and follow-up of these patients. Specific conditions discussed include sex cord stromal tumours (SCSTs), and germ cell tumours (GCTs). Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This is a clinical practice guideline for patients with vulvar cancer. The guideline examines the diagnosis, staging, treatment, and follow-up of these patients. Stages of vulvar cancer addressed include microinvasive (stage IA), early stage (> stage IA), and advanced stage (≥ stage 3). Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This is a clinical practice guideline for adult patients with lung cancer. Key areas discussed include screening and early detection, diagnostic procedures for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), staging, and management strategies. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This is a clinical practice guideline for patients who have been diagnosed with melanoma, and those who are at high risk for melanoma. The guideline provides recommendations on prevention, screening of high risk individuals, diagnosis, staging, treatment, and follow-up. Treatment strategies explored include surgery, radiation therapy, and adjuvant chemotherapy, and recommendations are separated based on disease type. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This is a clinical practice guideline for patients with non-melanoma skin cancer. The guideline discusses prevention, staging, treatment, and follow-up for these patients. Specific diseases discussed include basal cell carcinoma, squamous cell carcinoma, keratoacanthomas, Merkel cell tumours, Kaposi's sarcoma, extramammary Paget's disease (EMPD), and other non-melanoma skin cancers. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This guideline provides recommendations on the management of adult and pediatric patients who are experiencing febrile neutropenia as a result of cancer treatment. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

This is a clinical practice guideline for the work-up of suspicious colorectal masses following screening, as well as for the treatment of patients with diagnosed colorectal cancer. Treatment options discussed include surgery, adjuvant chemotherapy, and adjuvant radiotherapy. Recommendations are separated based on location and stage of disease, with the guideline specifically addressing localized rectal cancer, localized colon cancer, locally advanced unresectable colorectal cancer, up-front resectable metastatic colorectal cancer, and more.

This is a clinical practice guideline for patients with lymphoma, including Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), other aggressive non-Hodgkin lymphomas (NHLs), small lymphocytic leukemia (SLL)/chronic lymphocytic leukemia (CLL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma, and cutaneous lymphoma. The guideline examine the use of positron emission tomography/computed tomography (PET/CT), for staging purposes and for assessing treatment response.

This is a clinical practice guideline for patients with pancreatic ductal adenocarcinoma (PDAC). The guideline examines the screening, diagnosis, treatment and follow-up of these patients, with recommendations separated based on extent of disease (i.e. operable PDAC, locally advanced PDAC, or metastatic PDAC). Diagnostic methods examined include imaging and the use of serum tumour markers such as carbohydrate 19-9 antigen (CA19-9), and various treatment options are also discussed, including surgery and chemotherapy.

This is a clinical practice guideline for surveillance colonoscopy in adult populations identified with precancerous lesions detected by colonoscopy, those with a diagnosis of colorectal cancer (CRC), and/or people with a diagnosis of inflammatory bowel disease (ulcerative colitis or Crohn's disease). The guideline discusses the appropriate timing of colonoscopies in these patients. Other topics discussed include advances in colonoscopy, and the management of anxiety in patients who are undergoing the procedure. This guideline is wiki-based and is constantly updated as new evidence arises - this review pertains to the guideline as of August 30th, 2019.

This is a clinical practice guideline for the nutritional management of adult patients with head and neck cancer. The guideline examines appropriate access to nutritional care (screening and assessment), quality nutrition care and nutrition monitoring and evaluation. Outcomes of interest include treatment response, reduced adverse related consequences of malnutrition, and quality of life. This guideline is wiki-based and is constantly updated as new evidence arises - this review pertains to the guideline as of August 30th, 2019.

This is a clinical practice guideline for patients with prostate cancer. The guideline examines the diagnostic evaluation, classification and staging, treatment, and follow-up of these patients. Treatment for metastatic prostate cancer and castration-resistant prostate cancer are specifically discussed, as is the management of prostate-specific antigen-only recurrence after treatment with curative intent.

This is a clinical practice guideline for patients with non-muscle-invasive bladder cancer. The guideline examines the diagnosis, staging and classification, prediction of disease recurrence and progression, management, and follow-up of these patients. Specific management topics discussed include adjuvant treatment, treatment for failure of intravesical therapy, and radical cystectomy. Counselling of smoking cessation is also discussed.

This is a clinical practice guideline for patients with upper urinary tract urothelial cell carcinoma. The guideline examines the diagnosis, staging and classification systems, prognosis, management, and follow-up of these patients. Management options discussed include kidney-sparing surgery, radical nephroureterectomy, perioperative chemotherapy as an adjunct to radical nephroureterectomy, adjuvant radiotherapy after radical nephroureterectomy, adjuvant bladder instillation, metastasectomy, and systemic treatments.

This is a clinical practice guideline for patients with muscle-invasive and metastatic bladder cancer. The guideline examines recommendations for diagnostic evaluation and disease management, guidance for assessing comorbidities, and options for follow-up based on site of recurrence and level of evidence. Outcomes of interest are overall survival, mortality and quality of life.

This is a clinical practice guideline for patients with primary urethral carcinoma. The guideline discusses, diagnostic evaluation and staging, prognosis, treatment, and follow-up. Specific diagnostic techniques examined include pelvic magnetic resonance imaging (MRI), computed tomography (CT) of the thorax and abdomen, urethrocystoscopy, biopsy, and urinary cytology. Treatment options are compared to those for penile cancer, and include distal urethrectomy, radiotherapy, and chemotherapy.

This is a clinical practice guideline for adults with renal cell carcinoma (RCC). The guideline provides recommendations for the diagnosis and staging, treatment, and follow-up of these patients. Diagnostic methods compared include physical examination, laboratory testing, as well as imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI). The guideline also examines nephron-sparing surgery, radical nephrectomy, surveillance, ablative therapies, and adjuvant therapy, as potential treatment options.

This is a clinical practice guideline for patients with testicular cancer. The guideline examines the staging and classification, diagnosis, prognosis, management, and follow-up of these patients. Treatment methods for stage 1 germ cell tumours and metastatic germ cell tumours, the impact of treatment on fertility, as well as restaging and further treatment, are specifically discussed.

This is a clinical practice guideline for survivors of childhood, adolescent, and young adult cancer who have received hematopoietic cell transplantation (HCT). Topics discussed include growth hormone deficiency, thyroid disease, gonadal function, obesity, dyslipidemia, diabetes, bone health, ocular toxicity, and ototoxicity. Neurocognitive, pulmonary, cardiovascular, renal, gastrointestinal, dental, dermatological, and immunologic impacts are also addressed.

This is a clinical practice guideline for patients with squamous cell carcinoma of the vulva. The guideline examines diagnosis and referral, preoperative investigations, surgical management (i.e. local treatment, groin treatment and reconstructive surgery), sentinel lymph node procedures, radiation therapy, chemoradiation, systemic treatment, treatment of recurrent disease (i.e. vulvar recurrence, groin recurrence and distant metastases), and follow-up, in addition to providing information for discussions with patients and caregivers.

This is a clinical practice guideline for patients with uterine corpus cancer. These guideline discusses screening, surgery, adjuvant treatment, and advanced and recurrent disease with respect to endometrial carcinoma and uterine sarcoma. Other topics of interest include lymphadenectomy, fertility-sparing treatment, chemotherapy, and hormonal therapy.

This is a clinical practice guideline for male survivors of childhood, adolescent, and young adult (CAYA) cancers. The guideline specifically discusses treatments associated with increased risk of impaired spermatogenesis, testosterone deficiency, and physical sexual dysfunction. Surveillance strategies for these outcomes are examined, including which patients require surveillance, which surveillance modality should be used, frequency of surveillance, and what should be done when abnormalities are identified.

This is a clinical practice guideline for patients with localized prostate cancer who have undergone radical prostatectomy. The guideline focuses on the use of radiotherapy to reduce the risk of prostate cancer recurrence and clinical progression of cancer in these patients, and provides specifications concerning the timing of radiotherapy while emphasizing the importance of communicating the potential risks and benefits to patients.

This is a clinical practice guideline on enhanced recovery after colon and rectal cancer surgery. Recommendations address the appropriate preoperative, perioperative and postoperative interventions that contribute to improved patient recovery. Outcomes of interest include freedom from nausea, freedom from pain at rest, early return of bowel function, improved wound healing, and early hospital discharge.

This is a clinical practice guideline for adolescent, young adult (AYA), and adult patients with acute lymphoblastic leukemia (ALL). The guideline reviews the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers, and provides recommendations on risk assessment and stratification for risk-adapted therapy, as well as treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL. The guideline also provides recommendations for supportive care.

This is a clinical practice guideline for patients with acute myeloid leukemia (AML), including those with acute promyelocytic leukemia (APL). The guideline examines the initial evaluation of AML, risk stratification based on cytogenetics and molecular markers, management options, as well as supportive care. Management strategies are separated based on whether patients are above or below sixty years of age.

This is a clinical practice guideline for patients with cervical cancer. The guideline examines the staging, management, and follow-up of these patients. Specific management recommendations are made for stage T1a, T1b1/T2a1 cancer, clinically occult cervical cancer diagnosed after simple hysterectomy, early and locally advanced cervical cancer (LACC), primary distant metastatic disease, cervical cancer in pregnancy (CCIP), and recurrent disease. The use of fertility sparing treatment (FST) is also discussed.

This is a clinical practice guideline for adult patients with Merkel cell carcinoma. The guideline examines the staging and work-up, treatment, follow-up, and management of recurrence in these patients. Treatment options discussed include surgery, radiation, chemotherapy, and immunotherapy. Clinical scenarios including clinical node-negative, clinical node-positive, and metastatic are considered, as is sentinel lymph node biopsy protocol.

This is a clinical practice guideline for patients diagnosed with pancreatic adenocarcinoma. The main focus of the guideline is on adjuvant therapy for these patients who have undergone an R0 or R1 resection of their primary tumour, however the guideline also examines the general management of pancreatic cancer patients including initial assessment before therapy, which patients should be offered a potentially curative strategy with resection, when palliative care services should be initiated, and the frequency of follow-up care/surveillance.

This is a clinical practice guideline that aims to support clinicians in the evaluation of gastroenteropancreatic neuroendocrine tumour (GEP-NET) progression and treatment response. Topics of discussion include morphological imaging, molecular imaging, and pseudoprogression. Recommendations are provided pertaining to the imaging tools and optimal techniques that should used for monitoring patients and evaluating treatment response. Recommendations are also provided for the surveillance of patients with metastatic GEP-NETs, including the appropriate frequency of follow-up.

This is a clinical practice guideline for patients with colorectal cancer (CRC). The guideline provides recommendations for the management of emergencies including perforation and obstruction of the left or right colon. Ileostomy, colectomy, proctosigmoidectomy, and non-surgical procedures such as the use of self-expandable metallic stents (SEMSs), are discussed as potential management options.

This is a clinical practice guideline for patients with metastatic prostate cancer (mPCa). The guideline examines the management of patients with castration-naïve mPCa and those with metastatic castration-resistant prostate cancer (mCRPC). The use of predictive markers in mCRPC, sequencing treatment in mCRPC, managing men with oligometastases, as well as the staging and monitoring of mCRPC treatment, are also discussed.

This is a clinical practice guideline for the diagnosis, treatment and follow-up of adult patients with anaplastic gliomas. The guideline provides a diagnostic algorithm for anaplastic gliomas that considers isocitrate dehydrogenase 1/2 (IDH1/IDH2) missense mutations and 1p/19q co-deletions. Topics of discussion include radiology, histology and molecular biology, prognostic factors, surgery, radiotherapy, options for first-line systemic treatment, support treatment (e.g., corticoids and anticonvulsants), and follow-up.

This is the standard practice manual for the Alberta bone marrow and blood cell transplant program . The manual provides different recommendations for the use of bone marrow and blood cell transplantation based on disease type. Acute myeloid lymphoma, acute lymphoblastic leukemia, and myelodysplastic syndromes are all discussed.

This is a clinical practice guideline for patients who have been operated on for sporadic colorectal cancer (CRC) and for those in whom a low risk T1 CRC has been completely removed at endoscopy. The guideline discusses the endoscopic surveillance of these patients, and provides recommendations on the appropriate timing of endoscopy (i.e. in specific intervals following surgery), and the age at which to halt the use of surveillance endoscopy. Outcomes of interest include overall survival, CRC-specific survival, relapse-free survival, and adverse effects.

This is a clinical practice guideline for the optimal preoperative management of patients undergoing thoracic surgery, and primarily, lung resection. Topics covered in the guideline include preoperative counselling, nutritional screening, smoking cessation, prehabilitation for high-risk patients, avoidance of fasting, carbohydrate loading, avoidance of preoperative sedatives, venous thromboembolism prophylaxis, prevention of hypothermia, short-acting anesthetics to facilitate early emergence, regional anesthesia, nausea and vomiting control, opioid-sparing analgesia, euvolemic fluid management, minimally invasive surgery, early chest drain removal, avoidance of urinary catheters and early mobilization after surgery.

This is a clinical practice guideline for patients with non-small cell lung cancer (NSCLC). The guideline provides recommendations on the use of immunotherapy as treatment for these patients, using the immune checkpoint inhibitors pembrolizumab, nivolumab and atezolizumab. Specific topics discussed include appropriate patient selection, sequencing of therapies, response monitoring, adverse event management, and biomarker testing.

This is a clinical practice guideline for patients with prostate cancer. The guideline provides recommendations on the use of immunotherapy for the treatment of these patients, with recommendations separated based on the stage of disease (i.e. whether metastatic or non-metastatic, castration-sensitive or castration-resistant). Specific topics discussed include issues related to patient selection, monitoring of patients during and after treatment, and sequence/combination with other anti-cancer treatments.

This is a clinical practice guideline for adult patients who have undergone cancer treatment, and are at risk for developing secondary upper quadrant lymphedema (SUQL). The guideline provides recommendations for the diagnosis of SUQL, using methods such as clinical examination and patient-reported symptom assessments, bioimpedance analysis, circumferential measurement, water displacement, and imaging techniques such as magnetic resonance imaging (MRI), and computed tomography (CT). The primary outcomes of interest are decreases in both morbidity as well as activity and participation restrictions, and an increase in overall quality of life (QOL).

This is a clinical practice guideline for patients who have received initial treatment for chordomas, who are at risk for loco-regional recurrence. The guideline provides recommendations for pre-treatment assessment, resection of recurrent or progressive disease, radiotherapy of recurrence, other local therapies, follow-up, as well as for palliative, supportive and end-of-life care. Outcomes of interest include quality of life, recurrence-free survival, and overall survival.

This is a clinical practice guideline for women with uterine cancer. The guideline provides recommendations for the screening and prevention of uterine cancer in the general population and in high risk groups, as well as for the pathological work-up, management, and follow-up of patients with uterine cancer. Specific conditions discussed include endometrioid endometrial cancer, as well as non-endometrioid cancers such as uterine serous carcinoma, uterine clear cell carcinoma, and uterine carcinosarcoma.

This is a clinical practice guideline for patients with epithelial ovarian-type cancers (e.g. ovary, fallopian tube or peritoneal origin) and borderline tumours. This guideline addresses epithelial cancers of varying histological subtypes. The guideline covers the full continuum of care including screening and prevention, diagnosis, treatment options such as surgery, systemic therapy and chemotherapy, follow-up, as well as management of recurrent disease. The guideline also highlights the support needs for women with ovarian cancer.

This is a clinical practice guideline for adult patients with lung cancer who have been treated with surgery or systemic anti-cancer treatment such as chemotherapy or (external-beam) radiotherapy. The guideline provides recommendations for the symptomatic management of persistent, bothersome cough among theses patients. Multiple options for reducing cough are discussed, based on the etiology of the cough and the patient's response to various treatments.

This is a clinical practice guideline for the management of stage I to III melanoma in adult patients. The guideline discusses classification, resection margins, sentinel node biopsy, adjuvant treatments, initial work-up, follow-up, and the role of molecular biology tests. The guideline also compares the recommendations provided by other European guidelines and addresses any disparities in recommendations.

This is a clinical practice guideline on the perioperative care of patients undergoing surgery for adrenocortical carcinoma (ACC). Topics covered in the guideline include the optimal preoperative investigations, surgical approach, quality criteria of the operative note and pathological report, follow-up after surgery, surgical management of metastatic and/or recurrent ACC, and debulking or palliative surgery. The guideline also emphasizes the need for inclusion in collaborative and/or prospective databases to advance research and evidence on the topic.

This is a clinical practice guideline for the management of patients with advanced breast cancer (ABC), including those with locally advanced breast cancer (LABC) and metastatic breast cancer (MBC). The guideline provides recommendations for the management of these patients, and specifically discusses the use of chemotherapy, management of bone metastases, management of cancer related fatigue, as well as supportive and palliative care.

This is a clinical practice guideline for patients with hairy cell leukemia. The guideline provides recommendations regarding diagnosis, initial treatment, response assessment and additional therapy, second-line therapy for relapsed/refractory or progressive disease, and supportive care. The impact of infections, such as hepatitis B (HBV) is also discussed.

This is a clinical practice guideline for patients with T-cell lymphoma. The guideline examines the diagnostic workup, staging, treatment, follow-up, and supportive care for the most common subtypes of T-cell lymphoma. These subtypes include peripheral T-cell lymphomas (PTCLs), breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), mycosis fungoides (MF) and Sezary syndrome (SS), primary cutaneous CD30+ T-cell lymphoproliferative disorders, T-cell large granular lymphocytic leukemia (TGLL), adult T-cell leukemia/lymphoma (ATLL), T-cell prolymphocytic leukemia (TPLL), and extranodal NK/T-cell lymphomas (ENKL), nasal type.

This is a clinical practice guideline for patients with small cell lung cancer. The guideline examines the diagnosis, staging, prognostic factors, treatment, and surveillance of these patients. Treatment options discussed include systemic therapy, radiotherapy, and surgical resection. Systemic therapy is further examined in elderly patients, and as a second-line (and beyond) treatment. Radiotherapy treatments considered include thoracic radiotherapy, prophylactic cranial irradiation, and palliative radiotherapy.

This is a clinical practice guideline for patients with testicular germ cell tumours (GCTs). The guideline examines the clinical presentation, workup, primary treatment, and pathologic diagnoses of these patients. Separate recommendations are provided for different stages of pure seminomas and nonseminomas, and the guideline also discusses second-line and subsequent therapies for metastatic GCTs.

This is a clinical practice guideline for patients with primary mediastinal B-cell lymphoma. The guideline examines the staging, therapy, response assessment, relapse or refractory disease, and follow-up of these patients. The effect of chemotherapy on fertility and pregnancy is discussed, as well as thrombotic complications of superior vena cava obstruction (SVCO).

This is a clinical practice guideline for patients who have been operated on for a pheochromocytoma or a paraganglioma. The guideline discusses the long-term follow-up of these patients, and includes recommendations on diagnosing malignancy, perioperative work-up, duration of follow-up, monitoring methods, as well as specific considerations for pregnant women and patients who are frail and/or elderly.

This is a clinical practice guideline for adults with diffuse gliomas. Diagnosis, as well as treatment methods including chemotherapy, radiation therapy, and surgical procedures are discussed. The guideline provides general recommendations, as well as specific recommendations for low grade gliomas (WHO grade II), anaplastic gliomas (WHO grade III), and glioblastoma (WHO grade IV).

This is a clinical practice guideline for physicians who work on the prevention and treatment of colorectal cancer in the ambulatory and inpatient sector. The guideline provides recommendations for prevention, screening in asymptomatic populations as well as high risk populations, the role of endoscopy in the diagnosis of polyps and colorectal cancer, pre-operative diagnostics and surgery, adjuvant and neoadjuvant therapy, management of patients with metastases, palliative care and follow-up care.

This is a clinical practice guideline for women with vulvar cancer (VC) or vulvar intraepithelial neoplasia (VIN). The guideline provides recommendations for symptom management, with an emphasis on self-management interventions. Specific topics discussed include the handling of surgical wounds, as well as the management of acute postsurgical pain, postsurgical urinary symptoms, and lymphedema.

This is a clinical practice guideline for patients with meningiomas. Recommendations are provided regarding diagnosis, including radiological methods used, collection and storage of tissue, and histological verification. Different treatment and follow-up recommendations are also discussed, based on which World Health Organization (WHO) grade the meningioma is classified as (i.e. WHO grades I-III).

This is a clinical practice guideline for patients with renal cell carcinoma (RCC). The guideline discusses diagnosis, treatment, and follow-up, and provides specific recommendations on topics such as the primary treatment of RCC without metastases, systemic treatment for metastatic RCC, neoadjuvant/adjuvant therapy, as well as the resection and radiotherapy of metastases.

This is a clinical practice guideline for the diagnosis, treatment and follow-up of patients with gastrointestinal stromal tumours (GISTs). The guideline discusses the diagnosis of GISTs using radiology, histology and molecular biology, while also providing recommendations for the treatment of both localized and advanced disease. Surgery, adjuvant and neoadjuvant treatment options are specifically examined.

This is a clinical practice guideline for the management of soft tissue sarcoma (STS) in adult patients. The guideline pertains to the following five subtypes of STS: (1) STS of extremity, superficial/trunk, or head and neck, (2) retroperitoneal or intra-abdominal STS, (3) gastrointestinal stromal tumours (GISTs), (4) desmoid tumours, and (5) rhabdomyosarcoma (RMS). The guideline provides recommendations for diagnosis, staging, treatment, palliative care, and surveillance. Surgery, chemotherapy, and radiotherapy are all examined as treatment options.

This is a clinical practice guideline for patients with systemic mastocytosis (SM). The guideline provides recommendations on the diagnostic criteria for variants of SM, as well as for treatment and follow-up. Specific variants discussed include indolent SM, smoldering SM, aggressive SM, and SM with an associated hematological neoplasm.

This is a clinical practice guideline for patients with diagnosed or suspected thyroid carcinoma. The guideline discusses the initial workup, diagnosis, staging, treatment, and follow up of patients with differentiated, papillary, follicular, medullary, and anaplastic thyroid carcinoma, as well as Hurthle cell carcinoma. Surgery, radiation therapy, and systemic therapy are discussed as treatment options.

This is a clinical practice guideline for women with vulvar cancer, and particularly those with squamous cell carcinoma (SCC) of the vulva. The guideline examines diagnosis and workup, as well as primary treatment, adjuvant radiotherapy and chemotherapy, and surveillance of these patients. Treatment options are discussed for early-stage disease, locally advanced disease, and metastases beyond the pelvis.

This is a clinical practice guideline for adults and children with cancer-induced anemia (CIA). The guideline discusses the etiology of CIA, and examines the screening, evaluation, and treatment methods for reducing CIA in affected patients. Red blood cell transfusion, erythropoietic therapy, and iron monitoring and supplementation are discussed as treatment options.

This is a clinical practice guideline for adults with solid tumours and non-myeloid malignancies who are receiving myelosuppressive chemotherapy. The guideline examines the use of myeloid growth factors (MGFs) in these patients as a method for reducing the incidence of neutropenia. Topics of interest include the benefits and risks of MGFs, as well as their use in prophylactic, therapeutic, and post-transplant settings.

This is a clinical practice guideline for adolescents and young adults with cancer. The guideline discusses risk factors, screening, diagnosis, management, follow-up, supportive care, and palliative care for patients between 15 and 39 years of age. Unique issues discussed include adherence to treatment, the impact of cancer and its treatment on fertility, management of cancer during pregnancy, relationship management, and socioeconomic issues.

This is a clinical practice guideline for patients living with HIV (PLWH) who are diagnosed with cancer. The guideline focuses primarily on PLWH who develop non-small cell lung cancer (NSCLC), anal cancer, Hodgkin lymphoma, or cervical cancer. General advice is also provided regarding HIV management during cancer therapy, in addition to topics such as drug-drug interactions (DDI) between antiretroviral treatments and cancer therapies, initial workup, radiation therapy, surgical management, and supportive care.

This is a clinical practice guideline for older patients with cancer. The guideline provides recommendations for comprehensive geriatric assessments, as well as treatment modalities such as surgery, radiation therapy (RT), chemotherapy, and targeted therapy. Disease-specific issues are also addressed for breast cancer, central nervous system cancers, gastrointestinal cancers, genitourinary cancers, gynecological cancers, head and neck cancers, lung cancers, melanoma, and hematologic malignancies.

This is a clinical practice guideline for adult patients with esophageal cancer or cancer of the gastro-esophageal junction. The guideline provides recommendations on assessment, systemic therapy, surgical approaches, and post-curative therapy follow-up of these patients. The discussion of treatment is stratified by stage, performance status, and disease type. Chemotherapy regimens are also considered.

This is a clinical practice guideline for patients with polycythemia vera (PV). The guideline provides recommendations on diagnosis, risk stratification and management of PV. Specific topics discussed include the initial assessment, stage 1 investigations, considerations based on erythropoietin (EPO) levels, gene sequencing for congenital erythrocytosis, and cytoreductive therapy.

This is a clinical practice guideline for patients who have or are suspected of having primary central nervous system diffuse large B-cell lymphoma (PCNSL) located in the brain, spinal cord, cranial nerves, eyes or meninges. Specific topics discussed include diagnosis and imaging, treatment of primary CNS lymphoma, remission induction, consolidation treatment, follow-up, relapsed and refractory PCNSL, and neuropsychological assessments.

This is a clinical practice guideline for adults with newly-diagnosed or recurrent oesophago-gastric cancer. The guideline discusses clinical assessment, radical and palliative treatment, follow-up, nutritional support, and service organization. The primary outcomes of interest are increases in quality of life and survival.

This is a clinical practice guideline for the appropriate use of breast magnetic resonance imaging (MRI). The guideline examines indications for breast MRI use, such as for the screening of high risk individuals, for problem solving when mammographic, sonographic or clinical findings are suspicious but inconclusive, for the assessment of positive margins following breast cancer surgery or neoadjuvant chemotherapy, and for the assessment of breast implant integrity.

This is a clinical practice guideline for patients with cutaneous melanoma. The guideline examines the care of these patients throughout the cancer care continuum, including prevention and surveillance, diagnosis and prognosis, surgical management and staging, further investigations and non-surgical staging, adjuvant treatment of stage 2 and 3 melanoma, follow up of patients with stage 1, 2 and 3 melanoma, and management of advanced (unresectable stage 4 or 5) melanoma.

This clinical practice guideline is a focused update of the American Society of Clinical Oncology's 2016 adaptation of Cancer Care Ontario's guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer and adjuvant targeted therapy for breast cancer. New recommendations are provided on the addition of adjuvant capecitabine after completion of standard preoperative anthracycline- and taxane-based combination chemotherapy, the addition of 1 year of adjuvant pertuzumab to combination chemotherapy and trastuzumab, and the use of neratinib as extended adjuvant therapy in patients with early-stage human epidermal growth factor receptor 2 (HER2)-amplified or HER2-overexpressed breast cancer.

This clinical practice guideline is a focused update of the American Society of Clinical Oncology's 2016 guideline on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. The guideline specifically examines whether extended adjuvant therapy, including the use of aromatase inhibitors (AIs), improves clinically meaningful outcomes (e.g. disease-free survival, overall survival, quality of life, toxicity) after 5 years of sequential endocrine therapy in postmenopausal women with hormone receptor-positive early breast cancer.

This is a clinical practice guideline for men with metastatic non-castrate prostate cancer being considered for treatment with androgen-deprivation therapy (ADT). The guideline examines the addition of docetaxel or abiraterone to ADT, and the resulting effects on overall survival (OS), progression-free survival (PFS), failure-free survival (FFS), prostate-specific antigen (PSA) response, overall response rate, and quality of life (QOL).

This is a clinical practice guideline for patients with acute myeloid leukemia (AML), including those with acute promyelocytic leukemia (APL). The guideline examines the initial evaluation of AML, risk stratification based on cytogenetics and molecular markers, management options, as well as supportive care. Management strategies are separated based on whether patients are above or below sixty years of age.

This is a clinical practice guideline for patients with AIDS-related Kaposi sarcoma. The guideline examines diagnosis, staging, treatment, and follow-up, while also providing recommendations on HIV screening and HIV therapy during cancer treatment. Antiretroviral therapy (ART), topical therapies, intralesional chemotherapy, local incisions, radiation therapy, and systemic therapy are all discussed as treatment options.

This is a clinical practice guideline for patients with bladder cancer. Non-muscle-invasive urothelial bladder cancer, muscle-invasive urothelial bladder cancer, metastatic (Stage IVB) urothelial bladder cancer, non-urothelial carcinomas of the bladder, upper tract urothelial carcinoma (UTUC), urothelial carcinomas of the prostate, and primary carcinomas of the urethra are all specifically discussed. The guideline provides algorithms for diagnosis, staging, treatment, and follow-up.

This is a clinical practice guideline for patients with bone cancer. The guideline focuses on chordoma, chondrosarcoma, Ewing sarcoma, osteosarcoma, and provides recommendations for treating giant cell tumour of the bone (GCTB). Workup, treatment, surveillance, and relapsed disease are discussed for each of the types of bone cancer mentioned. Staging, high-grade undifferentiated pleomorphic sarcoma of bone, and immunotherapy for bone cancer are also considered.

This is a clinical practice guideline for patients with breast cancer. The guideline examines the staging, pathology assessment, and treatment approach for these patients. Pure non-invasive carcinomas (stage 0), stage 1, 2A, 2B or 3A (T3, N1, M0) invasive breast cancer, stage 3 invasive breast cancer, and stage 4 metastatic or recurrent breast cancer are discussed. Special situations including Paget's disease, phyllodes tumours of the breast, breast cancer during pregnancy, inflammatory breast cancer, and axillary breast cancer are also considered.

This is a clinical practice guideline for women with cervical cancer. The guideline examines the initial diagnosis and workup, staging, primary and adjuvant treatment, surveillance, and therapy following relapse for these patients. Treatment for metastatic disease is also discussed, as are the topics of incidental cervical cancer and the occurrence of cervical cancer in pregnant women.

This is a clinical practice guideline for patients with chronic myeloid leukemia (CML). The guideline discusses diagnosis and workup, staging, and management options for these patients, and includes specific considerations for children with CML. The guideline separates treatment options based on characteristics such as genetic profile, and phase (i.e. chronic phase, accelerated phase, and blast phase). Topics discussed include toxicities and response milestones for different treatment options.

This is a clinical practice guideline for patients with chronic lymphocytic leukemia, or small lymphocytic lymphoma. The guideline examines the diagnosis, staging, treatment, and follow-up of these patients. Prognosis and treatment algorithms are presented based on patient characteristics such as age, and genetic profile.

This is a clinical practice guideline for the management of colon cancer. Recommendations are made for diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, and management of recurrence. Principles for the management of metastatic disease are also provided.

This is a clinical practice guideline for the management of rectal cancer. The guideline provides recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, management of recurrent and metastatic disease, and patient surveillance. Outcomes of interest include safety and efficacy of treatment, adverse outcomes, and overall survival.

This is a clinical practice guideline for hepatobiliary cancers. The guideline examines the clinical management of patients with hepatocellular carcinoma (HCC), gallbladder cancer, as well as intrahepatic and extrahepatic cholangiocarcinoma. Risk factors, diagnosis, staging and prognosis, and treatment are discussed for the different conditions.

This is a clinical practice guideline for patients with renal cell carcinoma (RCC). The guideline specifically examines the initial evaluation, staging, diagnosis, clinical management options, and follow-up of patients with clear cell carcinoma and non-clear cell carcinoma. Pharmacologic agents discussed include pazopanib, sunitinib, and nivolumab.

This is a clinical practice guideline for patients with multiple myeloma. The guideline examines the primary therapy and surveillance/follow-up tests for both solitary plasmacytoma and smoldering (asymptomatic) myeloma, and the primary therapy and monitoring for active (symptomatic) myeloma. Stem cell transplants (SCT), including autologous SCT, tandem SCT, and allogeneic SCT, as well as follow-up after stem cell transplants, are also discussed. In addition, the guideline considers diagnostic tests, response criteria, maintenance therapy, treatment of progressive or relapsed myeloma, and supportive care treatment.

This is a clinical practice guideline for patients with Waldenström macroglobulinemia or lymphoplasmacytic lymphoma. The guideline examines the diagnosis, workup, primary treatment regimens, assessment of response to primary treatment, and follow-up after primary treatment. Regimens not toxic to stem cells and regimens with potential or unknown toxicity to stem cells are considered. Treatment of Immunoglobulin M (IgM) related peripheral neuropathy, maintenance therapy, and therapy for previously treated Waldenström macroglobulinemia are also discussed.

This is a clinical practice guideline for patients with myelodysplastic syndromes (MDS). The guideline discusses diagnostic classification, evaluation, prognostic stratification, therapeutic options, and recommended treatment approaches for MDS. There is a particular focus on supportive care, and the guideline also provides recommendations for the management of thrombocytopenia and iron overload, the treatment of related anemia, the use of low-intensity therapy (i.e. hypomethylating agents or biologic response modifiers and immunosuppressive therapy), and high-intensity therapy.

This is a clinical practice guideline for patients with myeloproliferative neoplasms. The guideline specifically examines the diagnosis, risk-stratification, treatment, and supportive care for patients with polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF). Risk-stratified treatment algorithms are provided for each disorder.

This is a clinical practice guideline for patients with neuroendocrine or adrenal tumours. The guideline discusses the diagnosis, staging, treatment, and follow-up of patients with sporadic neuroendocrine tumours, originating from organs such as the lungs, thymus, and gastrointestinal (GI) tract. The guideline also examines the role of the genetic syndrome, multiple endocrine neoplasia (MEN), in developing parathyroid, pituitary, and pancreatic tumours.

A clinical practice guideline on the diagnosis, workup, and treatment of patients who have been diagnosed with or are suspected of having primary cutaneous B-cell lymphomas (PCBCLs). The guideline focuses on the three main types of PCBCLs: primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle-center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, leg type). Recommendations for treatment are provided based on lymphoma type and whether treatment is for initial, relapsed, or refractory disease.

This is a clinical practice guideline for patients with Merkel cell carcinoma. The guideline provides recommendations on diagnosis, workup, staging, radiation therapy, chemotherapy, follow-up, and recurrence. Specific recommendations are provided for the postoperative management of primary tumours, management of the draining nodal basin, and treatment of distant metastatic disease.

This is a clinical practice guideline for patients with non-small cell lung cancer. The guideline examines the risk factors, classification factors, diagnostic evaluation, pathologic evaluation, staging, predictive and prognostic biomarkers, treatment, and surveillance of lung cancer. Treatment approaches considered include surgery, radiation therapy, and combined modality therapy. The discussion on initial therapy is stratified by disease stage.

This is a clinical practice guideline for patients with epithelial occult primary cancer. The guideline provides recommendations for the evaluation, workup, management, and follow-up of two pathologic diagnoses in patients with epithelial occult primary cancer: adenocarcinoma, or carcinoma not otherwise specified (NOS), and squamous cell carcinoma (SCC). Management options considered include chemotherapy, radiation therapy, locoregional therapeutic options, and specialized approaches, as well as supportive care and management of psychosocial distress.

This is a clinical practice guideline for patients with pancreatic adenocarcinoma. The guideline examines risk factors and genetic predisposition, pancreatic cancer screening, diagnosis and staging, systemic therapy approaches, radiation and chemoradiation approaches, surveillance of patients with resected disease, as well as palliative and supportive care. Management of metastatic disease, locally advanced disease, resectable and borderline resectable disease, and recurrent disease after resection is also considered.

This is a clinical practice guideline for the management of squamous cell carcinoma (SCC) of the penis. The guideline examines the diagnosis, treatment, and follow-up for patients with this form of cancer. Outcomes of interest include optimizing therapeutic efficacy and minimizing treatment-related morbidity.

This is a clinical practice guideline for patients undergoing major head and neck cancer surgery with free flap reconstruction. The guideline provides recommendations for the optimal perioperative care of these patients, focusing on topics such as preadmission education, preoperative nutritional status, perioperative nutritional care, prophylaxis against thromboembolism, antibiotic prophylaxis, postoperative nausea and vomiting prophylaxis, standard anesthetic protocol, pain management, postoperative wound care, postoperative pulmonary physical therapy, and more.

This is a clinical practice guideline for survivors of childhood cancer. The guideline provides recommendations for the endocrine treatment of hypothalamic-pituitary and growth disorders in these patients. Specific conditions discussed include impaired linear growth, growth hormone deficiency, central precocious puberty, hypogonadotropic hypogonadism, and thyroid-stimulating hormone deficiency.

This is a clinical practice guideline for adults who have been diagnosed with or are suspected of having basal cell carcinoma (BCC). The main focus of the guideline is on the most common approaches for the treatment of primary BCC, but it also includes recommendations on the treatment of recurrent tumours, appropriate biopsy techniques, staging, follow-up, and prevention of BCC.

This is a clinical practice guideline for patients with cutaneous squamous cell carcinoma (cSCC). The guideline provides recommendations for the evaluation and management of patients with cSCC. Topics of interest include biopsy techniques and histopathologic assessment, tumour staging, surgical and non-surgical management, follow-up and prevention of recurrence, and management of advanced disease.

This is a clinical practice guideline for the management of venous thromboembolism (VTE) and cardiovascular disease (CVD) in patients with multiple myeloma. The guideline provides recommendations on assessment, diagnosis, prevention, treatment, and follow-up for VTE and CVD. Risk factors and risk stratification for VTE and CVD are discussed. The guideline also highlights multiple myeloma treatments with side-effects related to VTE and CVD.

This is a clinical practice guideline for patients with aggressive pituitary tumours and carcinomas, which provides recommendations on diagnosis, treatment, and follow-up. Treatment options such as surgery, radiotherapy, and temozolomide are examined. Further guidance on dosing regimens, adverse effects, discontinuation, and combination chemotherapies is provided for temozolomide. Recurrence, non-responders, and systemic metastasis are also discussed.

This is a clinical practice guideline for adolescents and young adults with cancer. The guideline discusses risk factors, screening, diagnosis, management, follow-up, supportive care, and palliative care for patients between 15 and 39 years of age. Unique issues discussed include adherence to treatment, the impact of cancer and its treatment on fertility, management of cancer during pregnancy, relationship management, and socioeconomic issues.

This is a clinical practice guideline for older patients with cancer. The guideline provides recommendations for comprehensive geriatric assessments, as well as treatment modalities such as surgery, radiation therapy (RT), chemotherapy, and targeted therapy. Disease-specific issues are also addressed for breast cancer, central nervous system cancers, gastrointestinal cancers, genitourinary cancers, gynecological cancers, head and neck cancers, lung cancers, melanoma, and hematologic malignancies.

This is a clinical practice guideline on pneumococcal immunization for adult and pediatric cancer patients with solid tumours or hematologic cancers. The guideline provides recommendations on the type of vaccine and timing of immunization in relation to the type of treatment, therapy cycle, and severity of immunosuppression. Guidance is also provided on restrictions for immunization.

This is a clinical practice guideline for patients with thyroid cancer. The guideline examines the diagnosis, treatment, management, and follow-up of these patients. Topics of interest include a shift towards a standardized ultrasound/cytologic concordance system to guide investigation and management of thyroid nodules, acceptance of thyroid lobectomy as an option for many low risk thyroid cancers, acceptance of either no or lower dose radio-iodine treatment for many low risk thyroid cancers, and dynamic risk stratified follow-up for thyroid cancer.

This is a clinical practice guideline for adults with myeloma. The guideline examines the use and technical application of the latest imaging modalities at diagnosis and in the follow-up of patients with myeloma and plasmacytoma. Plain X-rays, whole body low-dose computed tomography (WBLDCT), and whole body magnetic resonance imaging (WB-MRI) are imaging techniques that are focused on.

This is a clinical practice guideline for adults and children who are receiving hematopoietic stem cell transplantation (HSCT) or are undergoing treatment for hematological malignancies. The guideline provides recommendations for the diagnosis, prevention, and management of common respiratory viral infections in these patients. Diseases discussed include influenza, respiratory syncytial virus (RSV), human metapneumovirus (HMPV), human parainfluenza virus (HPIV), and human rhinovirus (HRV).

This is a clinical practice guideline for patients with myeloma. The guideline examines the screening and management of physical and psychosocial consequences in these patients following completion of treatment. Recommendations are provided for long-term physical consequences, including infection and immunity, renal and urogenital complications, bone, endocrine and metabolic disorders, neurological and eye complications, cardiovascular and respiratory complications, dental and oral hygiene, gastroenterological and nutritional problems, and second primary malignancies. Psychosocial and rehabilitation considerations such as frailty, patient concerns and information provision, psychological well-being, pain and fatigue, and physical fitness and functionality are also discussed.

This is a clinical practice guideline for children with suspected or confirmed transient leukemia of Down syndrome (TL-DS). The guideline examines the clinical features and diagnosis of TL-DS, outcomes, risk factors for early death, and treatment of TL-DS, as well as monitoring for resolution of TL-DS and development of myeloid leukemia of Down syndrome (MI-DS). Fetal TL-DS, silent TL-DS and screening for mutations in the hematopoietic transcription factor gene GATA1 are also discussed.

This is a clinical practice guideline for patients with primary urethral carcinoma (UC). The guideline provides recommendations on the diagnosis and treatment of UC. Staging and classification systems for UC are also discussed. Outcomes of interest include detection rate, overall survival, complications, and toxicity.

This is a clinical practice guideline for the management of urothelial carcinoma of the upper urinary tract (UTUC). The guideline provides recommendations on diagnosis, staging, treatment, and follow-up. Prognostic factors, predictors of survival and recurrence, as well as risk stratification are also discussed. Outcomes of interest include diagnostic accuracy, overall survival, recurrence rates, and adverse effects.

This is a clinical practice guideline for the management of non-muscle-invasive bladder cancer. Recommendations are provided for diagnosis, staging, treatment, and follow-up. The guideline also discusses how to predict the short-term and long-term risks of disease recurrence and progression, as well as the stratification of patients into risk groups. Treatment options are presented based on these risk groups. Management of side effects is also discussed.

This is a clinical practice guideline for the management of muscle-invasive and metastatic bladder cancer. The guideline provides recommendations on prevention, staging, imaging, diagnosis, treatment, and follow-up. Treatment options such as neoadjuvant chemotherapy, radiotherapy, and radical surgery are discussed. Other topics of interest include risk factors, comorbidities, quality of life, and pelvic organ preservation techniques.

This is a clinical practice guideline for the diagnosis and treatment of patients with testicular cancer. The guideline examines the pathology of the illness, staging and classification systems, diagnostic evaluation, prognosis, disease management, and follow-up. Topics of interest include diagnostic tools, treatment with chemotherapy, and discussion of quality of life and long-term toxicities after curative treatment.

This is a clinical practice guideline for adult patients with prostate cancer. The guideline examines the screening, diagnosis, staging, treatment, and follow-up of these patients. Treatment options considered include deferred treatment, radical prostatectomy, definitive radiotherapy, and hormonal therapy. Management of metastatic prostate cancer, prostate cancer in older men, prostate-specific antigen-only recurrence after treatment, and castration-resistant prostate cancer are also discussed, as well as the epidemiology and etiology of prostate cancer, and quality of life outcomes.

This is a clinical practice guideline for adult patients with renal cell carcinoma (RCC). The guideline examines the staging, diagnosis, prognosis, treatment, and follow-up of these patients. Management recommendations are provided for treating localized RCC, locally advanced RCC, advanced/metastatic RCC, and recurrent RCC. The epidemiology, etiology, and pathology of RCC are also discussed.

This is a clinical practice guideline for patients who are receiving systemic anticancer therapy. The guideline examines the management of infusion reactions (IRs), which can be either allergic reactions to foreign proteins, or non-immune-mediated reactions. Specific topics discussed include risk assessment, diagnosis, management, how to document an IR, drugs which may frequently cause IRs, and cases of rechallenge.

This is a clinical practice guideline for patients with leptomeningeal metastases from solid tumours. The guideline discusses the diagnosis, treatment, and follow-up of these patients, and a treatment algorithm is presented based on life expectancy. Treatment options examined include systemic pharmacotherapy, intra-cerebrospinal fluid pharmacotherapy, focal radiotherapy (RT), and whole brain radiotherapy (WBRT).

This is a clinical practice guideline for patients aged 16 or older who have primary brain tumours or brain metastases. Specifically, the guideline examines the diagnoses and management of radiologically identified glioma, meningioma, and brain metastases. Follow-up care after treatment and supportive care are also discussed, and additional recommendations are provided on the referral of adults with primary brain tumours or brain metastases for neurological rehabilitation assessment.

This is a clinical practice guideline for the diagnosis and management of early and locally advanced breast cancer. The guideline provides recommendations on referral, diagnosis, preoperative assessment, genetic testing, surgical procedures, breast reconstruction, psychological support, and adjuvant therapies such as endocrine therapy and bisphosphonate therapy.

This is a clinical practice guideline for patients with head and neck cancer. The guideline examines the optimal perioperative care for patients undergoing head and neck cancer surgery with free flap reconstruction. Specific topics discussed include preadmission education, perioperative nutritional care, preoperative nutritional status, nutritional formulae, prophylaxis against thromboembolism, and antibiotic prophylaxis.

This clinical practice guideline discusses the prevention and management of chemotherapy induced nausea and vomiting (CINV) in pediatric cancer patients. Acute, delayed, anticipatory, breakthrough and refractory CINV are discussed. Recommendations are provided on assessment as well as pharmacological and non-pharmacological interventions. Antiemetic dosing recommendations are also provided.

This is a clinical practice guideline for the prevention and management of constipation in pediatric cancer patients. Pharmacological and non-pharmacological treatment options (including dosing recommendations) are discussed. The management of refractory opioid-induced constipation is also examined.

This is a clinical practice guideline for pediatric cancer patients who are receiving chemotherapy. Guidance is provided for the diagnosis and treatment of chemotherapy-induced diarrhea in these patients. Risk factors, grading of diarrhea, dietary modifications during diarrhea, and anti-diarrheal agents are also discussed.

This is a clinical practice guideline for patients who have been treated for non-metastatic renal cell carcinoma (RCC). The guideline examines the follow-up of these patients, and recommendations are provided for surveillance, clinical assessment, blood biochemistry tests, and imaging techniques.

This is a clinical practice guideline for the management of colon cancer. Recommendations are made for diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, and management of recurrence. Principles for the management of metastatic disease are also provided.

This is a clinical practice guideline for the management of rectal cancer. The guideline provides recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, management of recurrent and metastatic disease, and patient surveillance. Outcomes of interest include safety and efficacy of treatment, adverse outcomes, and overall survival.

This is a clinical practice guideline for adults with esophageal or esophagogastric junction cancer. The guideline examines the initial workup, histological staging, primary treatment, and follow-up of both squamous cell carcinoma and adenocarcinoma. Treatment modalities discussed include surgery, radiation therapy, combined modality therapy, chemotherapy, and targeted therapies.

This is a clinical practice guideline for patients with gastric cancer. The guideline examines the pathology, initial workup, staging, treatment, follow-up, and supportive care of these patients. Treatment options discussed include lymph node dissection, laparoscopic resection, endoscopy, radiation therapy, combined modality therapy, chemotherapy (preoperative, perioperative, and postoperative), and targeted therapies.

This is a clinical practice guideline for patients with hairy cell leukemia. The guideline provides recommendations regarding diagnosis, initial treatment, response assessment and additional therapy, second-line therapy for relapsed/refractory or progressive disease, and supportive care. The impact of infections, such as hepatitis B (HBV) is also discussed.

This is a clinical practice guideline for patients with head and neck cancers. The guideline examines workup and staging, treatment, and follow-up for various head and neck cancers including cancer of the lip, oral cavity, oropharynx, hypopharynx, nasopharynx, and larynx, as well as paranasal tumours, very advanced head and neck cancers, occult primary cancer, salivary gland tumours, and mucosal melanoma of the head and neck. Nutrition, supportive care, comorbidities, quality of life, and dental evaluation and management are also discussed.

This is a clinical practice guideline for hepatobiliary cancers. The guideline examines the clinical management of patients with hepatocellular carcinoma (HCC), gallbladder cancer, as well as intrahepatic and extrahepatic cholangiocarcinoma. Risk factors, diagnosis, staging and prognosis, and treatment are discussed for the different conditions.

This is a clinical practice guideline for adults with classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). The guideline discusses the clinical management of patients with CHL and NLPHL, focusing on patients who do not have serious intercurrent disease. Treatment options examined include chemotherapy, high dose therapy and autologous stem cell rescue (HDT/ASCR), and involved site radiation therapy (ISRT).

This is a clinical practice guideline for patients with renal cell carcinoma (RCC). The guideline specifically examines the initial evaluation, staging, diagnosis, clinical management options, and follow-up of patients with clear cell carcinoma and non-clear cell carcinoma. Pharmacologic agents discussed include pazopanib, sunitinib, and nivolumab.

This is a clinical practice guideline for patients with multiple myeloma. The guideline examines the primary therapy and surveillance/follow-up tests for both solitary plasmacytoma and smoldering (asymptomatic) myeloma, and the primary therapy and monitoring for active (symptomatic) myeloma. Stem cell transplants (SCT), including autologous SCT, tandem SCT, and allogeneic SCT, as well as follow-up after stem cell transplants, are also discussed. In addition, the guideline considers diagnostic tests, response criteria, maintenance therapy, treatment of progressive or relapsed myeloma, and supportive care treatment.

This is a clinical practice guideline for patients with Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma. The guideline examines the diagnosis, workup, primary treatment regimens, assessment of response to primary treatment, and follow-up after primary treatment. Regimens not toxic to stem cells and regimens with potential or unknown toxicity to stem cells are considered. Treatment of Immunoglobulin M (IgM) related peripheral neuropathy, maintenance therapy, and therapy for previously treated Waldenstrom's macroglobulinemia are also discussed.

This is a clinical practice guideline for patients with myelodysplastic syndromes (MDS). The guideline discusses diagnostic classification, evaluation, prognostic stratification, therapeutic options, and recommended treatment approaches for MDS. There is a particular focus on supportive care, and the guideline also provides recommendations for the management of thrombocytopenia and iron overload, the treatment of related anemia, the use of low-intensity therapy (i.e. hypomethylating agents or biologic response modifiers and immunosuppressive therapy), and high-intensity therapy.

This is a clinical practice guideline for patients with myeloproliferative neoplasms. The guideline specifically examines the diagnosis, risk-stratification, treatment, and supportive care for patients with polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF). Risk-stratified treatment algorithms are provided for each disorder.

This is a clinical practice guideline for patients with neuroendocrine or adrenal tumours. The guideline discusses the diagnosis, staging, treatment, and follow-up of patients with sporadic neuroendocrine tumours, originating from organs such as the lungs, thymus, and gastrointestinal (GI) tract. The guideline also examines the role of the genetic syndrome, multiple endocrine neoplasia (MEN), in developing parathyroid, pituitary, and pancreatic tumours.

A clinical practice guideline on the diagnosis, workup, treatment and surveillance of B-cell lymphoma (BCL) in pediatric and adult patients. The guideline focuses on the most common B-cell lymphomas: follicular lymphoma (FL), marginal zone lymphomas (MZL), nodal MZL, splenic MZL, gastric MALT lymphoma, mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), AIDS-related B-cell lymphoma, post-transplant lymphoproliferative disorders, and Castleman's disease. Additional consideration is paid to the classification systems used in NHL, the role of PET scans in assessment and staging, principles of radiation therapy, and supportive care considerations.

This is a clinical practice guideline for patients with T-cell lymphoma. The guideline examines the diagnostic workup, staging, treatment, follow-up, and supportive care for the most common subtypes of T-cell lymphoma. These subtypes include peripheral T-cell lymphomas (PTCLs), breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), mycosis fungoides (MF) and Sézary syndrome (SS), primary cutaneous CD30+ T-cell lymphoproliferative disorders, T-cell large granular lymphocytic leukemia (TGLL), adult T-cell leukemia/lymphoma (ATLL), T-cell prolymphocytic leukemia (TPLL), and extranodal NK/T-cell lymphomas (ENKL), nasal type.

This is a clinical practice guideline for patients with non-small cell lung cancer. The guideline examines the risk factors, classification factors, diagnostic evaluation, pathologic evaluation, staging, predictive and prognostic biomarkers, treatment, and surveillance of lung cancer. Treatment approaches considered include surgery, radiation therapy, and combined modality therapy. The discussion on initial therapy is stratified by disease stage.

This is a clinical practice guideline for patients with epithelial occult primary cancer. The guideline provides recommendations for the evaluation, workup, management, and follow-up of two pathologic diagnoses in patients with epithelial occult primary cancer: adenocarcinoma, or carcinoma not otherwise specified (NOS), and squamous cell carcinoma (SCC). Management options considered include chemotherapy, radiation therapy, locoregional therapeutic options, and specialized approaches, as well as supportive care and management of psychosocial distress.

This is a clinical practice guideline for adult patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Recommendations are provided for screening, staging, diagnosis, treatment, and follow-up. Treatment options discussed include debulking surgery, chemotherapy, and radiation therapy. Management of drug reactions is also discussed.

This is a clinical practice guideline for patients with pancreatic adenocarcinoma. The guideline examines risk factors and genetic predisposition, pancreatic cancer screening, diagnosis and staging, systemic therapy approaches, radiation and chemoradiation approaches, surveillance of patients with resected disease, as well as palliative and supportive care. Management of metastatic disease, locally advanced disease, resectable and borderline resectable disease, and recurrent disease after resection is also considered.

This is a clinical practice guideline for the management of squamous cell carcinoma (SCC) of the penis. The guideline examines the diagnosis, treatment, and follow-up for patients with this form of cancer. Outcomes of interest include optimizing therapeutic efficacy and minimizing treatment-related morbidity.

This is a clinical practice guideline for patients with small cell lung cancer. The guideline examines the diagnosis, staging, prognostic factors, treatment, and surveillance of these patients. Treatment options discussed include systemic therapy, radiotherapy, and surgical resection. Systemic therapy is further examined in elderly patients, and as a second-line (and beyond) treatment. Radiotherapy treatments considered include thoracic radiotherapy, prophylactic cranial irradiation, and palliative radiotherapy.

This is a clinical practice guideline for patients with testicular germ cell tumours (GCTs). The guideline examines the clinical presentation, workup, primary treatment, and pathologic diagnoses of these patients. Separate recommendations are provided for different stages of pure seminomas and nonseminomas, and the guideline also discusses second-line and subsequent therapies for metastatic GCTs.

This is a clinical practice guideline for patients with thymomas and thymic carcinomas. The guideline examines the diagnosis, staging, and treatment these mediastinal tumours. Surgical resection and radiation therapy are discussed as treatment options.

This is a clinical practice guideline for patients with diagnosed or suspected thyroid carcinoma. The guideline discusses the initial workup, diagnosis, staging, treatment, and follow up of patients with differentiated, papillary, follicular, medullary, and anaplastic thyroid carcinoma, as well as Hürthle cell carcinoma. Surgery, radiation therapy, and systemic therapy are discussed as treatment options.

This is a clinical practice guideline for women with vulvar cancer, and particularly those with squamous cell carcinoma (SCC) of the vulva. The guideline examines diagnosis and workup, as well as primary treatment, adjuvant radiotherapy and chemotherapy, and surveillance of these patients. Treatment options are discussed for early-stage disease, locally advanced disease, and metastases beyond the pelvis.

This is a clinical practice guideline for adults with any type of cancer. The guideline focuses on the screening, assessment, and treatment of cancer-related pain. Specific topics discussed include universal pain screening, management of pain in both opioid-naïve and opioid-tolerant patients, management of opioid-induced adverse effects, procedure-related pain and anxiety, management strategies for specific cancer pain syndromes, adjuvant analgesics for neuropathic pain, psychosocial support, and education for both patients and caregivers.

This is a clinical practice guideline for adults and children with cancer-induced anemia (CIA). The guideline discusses the etiology of CIA, and examines the screening, evaluation, and treatment methods for reducing CIA in affected patients. Red blood cell transfusion, erythropoietic therapy, and iron monitoring and supplementation are discussed as treatment options.

This is a clinical practice guideline for adults and children experiencing cancer-related fatigue (CRF). The guideline discusses screening for CRF, as well as evaluation approaches using focused history, assessment of treatable contributing factors, and patient clinical status. General strategies for managing CRF are discussed, and the guideline examines pharmacological and non-pharmacological treatments for patients based on their placement within the care continuum (i.e. active treatment, post-treatment, and end-of-life).

This is a clinical practice guideline for adults with solid tumours and non-myeloid malignancies who are receiving myelosuppressive chemotherapy. The guideline examines the use of myeloid growth factors (MGFs) in these patients as a method for reducing the incidence of neutropenia. Topics of interest include the benefits and risks of MGFs, as well as their use in prophylactic, therapeutic, and post-transplant settings.

This is a clinical practice guideline for patients living with HIV (PLWH) who are diagnosed with cancer. The guideline focuses primarily on PLWH who develop non-small cell lung cancer (NSCLC), anal cancer, Hodgkin lymphoma, or cervical cancer. General advice is also provided regarding HIV management during cancer therapy, in addition to topics such as drug-drug interactions (DDI) between antiretroviral treatments and cancer therapies, initial workup, radiation therapy, surgical management, and supportive care.

This is a clinical practice guideline discussing influenza immunization for adult and pediatric cancer patients. The guideline provides guidance on the timing of influenza immunization in relation to severity of immunosuppression and chemotherapy schedules, number of administrations, types of influenza vaccines, and contraindications and precautions for immunization. Recommendations for the immunization of family members and hospital or clinic staff are also provided.

This is a clinical practice guideline for adult patients with four or fewer brain metastases. The guideline examines the important prognostic factors for assessing and managing these patients, the role of surgery and radiotherapy in the management of oligometastatic disease, and the appropriate follow-up and surveillance strategy. Treatments considered include whole brain radiation therapy (WBRT) and stereotactic radiosurgery (SRS), both alone and in conjunction.

This is a clinical practice guideline for patients with renal cell carcinoma (RCC). The guideline examines the clinical management of RCC, including diagnosis, treatment, and follow up. The primary outcomes of interest are survival, recurrence, and quality of life.

This is a clinical practice guideline for patients who have been diagnosed with or are suspected of having advanced/metastatic prostate cancer. The guideline provides guidance on the staging, treatment, and follow up procedures for these patients. Topics of interest include radiotherapy techniques, the use of bone scans to assist in staging, and follow-up using active surveillance within a cancer clinic.

This is a clinical practice guideline for adult men with a suspicion or recent diagnosis of localized prostate cancer. The guideline examines staging, treatment options, and follow-up for these patients. Management is discussed for low, intermediate, and high-risk disease. Treatment options considered include variations of radical prostatectomy, brachytherapy, external beam radiotherapy, cryosurgery, and active surveillance.

This is a clinical practice guideline for adult patients with head and neck cancer. The guideline examines oral and dental care assessment and management of patients before, during, and after cancer treatment. Topics addressed include pain, xerostomia, speech and swallowing disorders, oral hygiene, and functional capacity. The primary outcome of interest is quality of life.

A clinical practice guideline on the diagnosis, staging, treatment and management of adult patients who are suspected of having, or have been diagnosed with, chronic myelogenous leukemia (CML). Treatment options examined include the use of tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, dasatinib, bosutinib, and ponatinib, as well as allogeneic stem cell transplant (SCT) and Interferon-a (IFNa). Special consideration is paid to the use of TKIs in the treatment of elderly patients with CML.

This is a clinical practice guideline for adult patients who have been diagnosed with or are suspected of having lymphoma. The guideline discusses Hodgkin lymphoma, as well as the most common non-Hodgkin lymphomas (T-cell and B-cell). Recommendations are provided on diagnosis, staging, treatment, management, and follow up care.

This is a clinical practice guideline for adult patients with chronic lymphocytic leukemia. The guideline examines the diagnostic and staging criteria, treatment strategies, and follow-up and supportive care practices for these patients. First and second line treatment options are discussed for newly diagnosed, relapsed, and refractory disease.

This is a clinical practice guideline for adult patients with desmoid tumours. The guideline provides recommendations for diagnosis, staging procedures, treatment, and follow-up. Treatment options including active surveillance, surgery, radiation therapy, and chemotherapy are examined. Topics of interest include desmoid tumours occurring during pregnancy, pain management, and rehabilitation.

This is a clinical practice guideline for the management of soft tissue sarcoma (STS) in adult patients. The guideline pertains to the following five subtypes of STS: (1) STS of extremity, superficial/trunk, or head and neck, (2) retroperitoneal or intra-abdominal STS, (3) gastrointestinal stromal tumours (GISTs), (4) desmoid tumours, and (5) rhabdomyosarcoma (RMS). The guideline provides recommendations for diagnosis, staging, treatment, palliative care, and surveillance. Surgery, chemotherapy, and radiotherapy are all examined as treatment options.

This clinical practice guideline provides recommendations on the follow-up of patients with endometrial cancer who are clinically disease free after receiving primary treatment. The guideline reviews symptomatic signs of possible recurrence. Recommendations are provided on follow-up intervals and diagnostic interventions, stratified by risk of recurrence.

This clinical practice guideline is an endorsement of the American Thyroid Association's 2015 guideline titled Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. The guideline provides recommendations on management of patients thyroid nodules and differentiated thyroid cancers. Topics include evaluation of thyroid nodules to determine the presence of malignancy, and management of differentiated thyroid cancer including surgery, radioactive iodine (RAI) therapy, hormonal therapy, external beam radiation therapy (EBRT), and systemic treatment.

This is a clinical practice guideline for the empirical management of fever and neutropenia (FN) in children with cancer, and those who have received hematopoietic stem-cell transplantation (HSCT). The guideline examines initial presentation, ongoing management, and empirical antifungal therapy. Topics of interest include risk stratification to define patients with high-risk invasive fungal disease (IFD), recommended biomarkers and radiologic investigations for the evaluation of IFD in prolonged FN, and empirical antifungal therapy in IFD low-risk patients with prolonged FN.

This is a clinical practice guideline for adolescent, young adult (AYA), and adult patients with acute lymphoblastic leukemia (ALL). The guideline reviews the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers, and provides recommendations on risk assessment and stratification for risk-adapted therapy, as well as treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL. The guideline also provides recommendations for supportive care.

This is a clinical practice guideline for patients with acute myeloid leukemia (AML), including those with acute promyelocytic leukemia (APL). The guideline examines the initial evaluation of AML, risk stratifications based on cytogenetics and molecular markers, management options, as well as supportive care. Management strategies are separated based on whether patients are above or below sixty years of age.

This is a clinical practice guideline for patients with AIDS-related Kaposi sarcoma. The guideline examines diagnosis, staging, treatment, and follow-up, while also providing recommendations on HIV screening and HIV therapy during cancer treatment. Antiretroviral therapy (ART), topical therapies, intralesional chemotherapy, local incisions, radiation therapy, and systemic therapy are all discussed as treatment options.

This clinical practice guideline is for the management of squamous cell anal carcinoma. The guideline provides recommendations on staging, treatment, and follow-up. The effectiveness of treatment options such as surgery, chemotherapy, and radiation therapy are compared. Guidance is also provided on dosing regimens, treatment of recurrence, and surveillance following treatment of recurrence.

This is a clinical practice guideline for patients with bladder cancer. Non-muscle-invasive urothelial bladder cancer, muscle-invasive urothelial bladder cancer, metastatic (Stage IVB) urothelial bladder cancer, non-urothelial carcinomas of the bladder, upper tract urothelial carcinoma (UTUC), urothelial carcinomas of the prostate, and primary carcinomas of the urethra are all specifically discussed. The guideline provides algorithms for diagnosis, staging, treatment, and follow-up.

This is a clinical practice guideline for patients with primary bone cancer. The guideline examines systemic therapy agents and radiation therapy for chordoma, chondrosarcoma, Ewing sarcoma, osteosarcoma, and giant-cell tumours of bone (GCTB). The guideline also discusses the management of relapsed disease.

This is a clinical practice guideline for women with breast cancer. The guideline examines staging, pathology assessment, and treatment approaches for pure noninvasive carcinomas, stage I, IIA, IIB, IIIA, or III invasive breast cancer, and stage IV metastatic or recurrent breast cancer. Special situations considered include Paget's disease, phyllodes tumours of the breast, breast cancer during pregnancy, inflammatory breast cancer, and axillary breast cancer.

This is a clinical practice guideline for women with cervical cancer. The guideline examines the initial diagnosis and workup, staging, primary and adjuvant treatment, surveillance, and therapy following relapse for these patients. Treatment for metastatic disease is also discussed, as are the topics of incidental cervical cancer and the occurrence of cervical cancer in pregnant women.

This is a clinical practice guideline for patients with chronic lymphocytic leukemia, or small lymphocytic lymphoma. The guideline examines the diagnosis, staging, treatment, and follow-up of these patients. Prognosis and treatment algorithms are presented based on patient characteristics such as age, and genetic profile.

This is a clinical practice guideline for patients with chronic myeloid leukemia (CML). The guideline discusses diagnosis and workup, staging, and management options for these patients, and includes specific considerations for children with CML. The guideline separates treatment options based on characteristics such as genetic profile, and phase (i.e. chronic phase, accelerated phase, and blast phase). Topics discussed include toxicities and response milestones for different treatment options.

This is a clinical practice guideline for the management of non-metastatic muscle-invasive urothelial bladder cancer in adults. The guideline examines the initial evaluation, treatment, follow-up, and survivorship of affected patients, and discusses approaches to counseling and the role of patient preferences throughout. Specific treatment options considered include neoadjuvant and adjuvant chemotherapy, radical cystectomy, pelvic lymphadenectomy, and bladder preserving approaches such as maximal transurethral resection of bladder tumours, partial cystectomy, primary radiation therapy, and multi-modal bladder preserving therapy.

This is a clinical practice guideline for adults with cancer who may be considering cardiotoxic anticancer therapies. The guideline examines surveillance and monitoring approaches for cardiac dysfunction in survivors of adult-onset cancers, both during and after treatment. Determining which patients are at risk for developing cardiac dysfunction, and identifying strategies to minimize risk before and during the administration of potentially cardiotoxic therapy, are also discussed.

This is a provisional clinical opinion (PCO) for chemotherapy-naive men with castration-resistant prostate cancer (CRPC). This PCO examines second-line hormonal therapy and provides recommendations on staging, treatment, follow-up, and palliative care for men with CRPC. Outcomes of interest include overall survival, adverse events, quality of life, and treatment efficacy (defined as response in prostate-specific antigen values).

This is a clinical practice guideline for the management of localized prostate cancer. The guideline provides a clinical framework stratified by cancer severity to guide the care plan and reviews management options including active surveillance, observation/watchful waiting, prostatectomy, radiotherapy, cryosurgery, high intensity focused ultrasound (HIFU), and focal therapy. Shared decision making is highlighted, and guidance is provided on outcome expectations and management.

This clinical practice guideline provides recommendations for breast reconstruction in women following mastectomy for the prevention or treatment of breast cancer. The guideline discusses patient education, eligibility for reconstruction, timing of reconstruction, factors that enhance recovery from reconstruction, post-reconstruction surveillance, and measuring outcomes of construction. The benefits and risks of implant-based, autologous flap, and combination reconstruction procedures are examined. The guideline also discusses the extent to appropriately perform mastectomy.

This is a clinical practice guideline for the assessment of liver metastases. The guideline provides recommendations regarding the appropriateness of imaging modalities and the optimization of imaging parameters for specific clinical scenarios, including diagnosis, staging, and surveillance. Outcomes of interest include accuracy in characterizing and detecting liver lesions, length of examination, and potential adverse health effects, as well as surveillance sensitivity, specificity, and reproducibility.

This is a clinical practice guideline for women with epithelial ovarian cancers, specifically focusing on patients with type-2 ovarian cancers. The guideline examines diagnostic imaging methods, used for both staging and evaluating potential recurrence. Imaging modalities discussed include x-ray, magnetic resonance imaging (MRI), fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), and computed tomography (CT).

This is a clinical practice guideline for patients who have received treatment for prostate cancer. The guideline examines the various imaging modalities that can be effectively used for the follow-up of these patients. Variations of imaging modalities such as transrectal ultrasound (TRUS), magnetic resonance imaging (MRI), and computed tomography (CT) are discussed, and the appropriateness of different techniques is examined for different clinical situations.

This is a clinical practice guideline for recurrent Hodgkin lymphoma. The guideline provides recommendations for the treatment of patients with early relapsed or progressive disease. Areas of focus include: stem cell transplantation, the role of radiation therapy, and chemotherapy.

This clinical practice guideline provides recommendations for the diagnosis, treatment, and follow-up of epithelial ovarian cancer. This guideline covers: carcinoma of the ovary, fallopian tube and primary peritoneal carcinoma; epithelial carcinoma, e.g. serious, mucinous, clear cell or endometrioid histology; borderline and invasive disease, diagnosis and first-line treatment; and follow-up after treatment. Recommendations consider patient values and preferences when treated for ovarian cancer.

This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes: follicular lymphoma, MALT lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma, and peripheral T-cell lymphoma. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.

This is a clinical practice guideline for patients with non-muscle invasive bladder cancer. Recommendations are provided on diagnostic procedure, risk stratification, variant histologies, urine markers, and treatment options including TURBT/Repeat resection, intravesical therapy, BCG/maintenance, and chemotherapy BCG combinations. BCG relapse and salvage regimens are reviewed as is the role of cystectomy and cystoscopy. Additionally, recommendations are provided for risk adjusted surveillance and follow-up strategies.

This is a clinical practice guideline to guide appropriate prescribing of filgrastim in adults. The guidelines looks at a variety of disease sites and is intended as a guide to facilitate a shared approach to the appropriate use of filgrastim. In order provide clarity surrounding the indications in which filgrastim should be used, the recommendations are presented by disease site.

This is a clinical practice guideline for patients with testicular germ cell tumours (GCTs). The guideline examines appropriate management and follow-up strategies for different stages of the two main histological types of testicular GCTs: seminomas and nonseminomas. Outcomes of interest include recurrence and overall survival.

A clinical practice guideline for the management of adult onset sarcoma. The guideline examines the diagnosis, staging, treatment, and follow-up options for sarcoma. Imaging modalities for the purpose of diagnosis and staging are compared, while the importance of multidisciplinary care and the effects of delayed referrals to specialists are discussed. In addition, pre-operative and post-operative radiotherapy are compared, and the guideline also examines adjuvant and systemic chemotherapy, as well as surgical procedures. This guideline is wiki-based and is constantly updated as new evidence arises - this review pertains to the guideline as of April 23, 2018.

This is a clinical practice guideline for adult and pediatric patients who receive antineoplastic agents or radiation therapy for cancer. The guideline examines important developments in antiemetic management options for patients undergoing the above treatments. Comparisons are made between antiemetic management options on the basis of potential benefits, potential harms, and quality of evidence. Outcomes of interest include new evidence regarding antiemetic efficacy and new antiemetic management options.

This is a clinical practice guideline for oncology clinicians on how to use effective communication to optimize the patient-clinician relationship, patient and clinician well-being, and family well-being. The guideline examines the core communication skills and tasks that apply across the continuum of cancer care. Topics include the discussion of goals of care and prognosis, treatment selection, end-of-life care, facilitating family involvement in care, and clinician training in communication skills.

This is a clinical practice guideline for patients aged 15 or older with acute lymphoblastic leukemia (ALL). The guideline reviews diagnosis, workup and risk stratification, treatment and consolidation therapy stratified by age and Philadelphia chromosome presence/absence, surveillance, treatment for relapse/refractory disease, and supportive care. The guideline discusses typical immunophenotyping panels for all major subtypes, and minimal residual disease assessment. Evaluation and treatment of extra medullary involvement is also reviewed.

This clinical practice guideline provides recommendations for the diagnosis and treatment of acute myeloid leukemia (AML). Induction therapy and post-remission (consolidation) therapy are reviewed with recommendations stratified by risk and age. Specific recommendations are provided for the management of acute promyelocytic leukemia (APL). The guideline also discusses therapy for relapse, evaluation and treatment of CNS leukemia, and supportive care.

This is a clinical practice guideline for patients with anal carcinoma. Risk factors are discussed and recommendations are provided on risk reduction including HIV immunization, work up, management, and follow-up care. Treatment options are reviewed, with specific recommendations provided for primary treatment of: non-metastatic anal carcinoma, anal canal cancer, and anal margin cancer, as well as treatment for metastatic cancer and for locally progressive or recurrent anal carcinoma. Special considerations are made regarding treatment of anal cancer in patients with HIV/AIDS.

This clinical practice guideline discusses evaluation, treatment (primary and secondary) options, and follow-up care for patients with bladder cancer. Specific workup and treatment recommendations are provided for non-muscle invasive disease, muscle invasive disease, upper genitourinary tract (GU) tumours, urothelial carcinomas of the prostate, and primary carcinoma of the urethra. Non-urothelial carcinomas of the bladder are also discussed.

This clinical practice guideline reviews workup and treatment of bone cancer, with specific recommendations provided for chondrosarcoma, chordoma, Ewing's sarcoma family of tumors, and osteosarcoma. Surveillance and relapse is also reviewed. An overview of systemic therapy agents is provided, and principles of radiation therapy are discussed.

This clinical practice guideline provides recommendations on esophageal and esophagogastric junction (EGJ) cancers, including: a review of hereditary cancer predisposition syndromes associated with increased risk for esophageal and EGJ cancers, staging and pathology, imaging, and treatment including surgery, radiation therapy, combined modality therapy, chemotherapy, and targeted therapies. Surveillance, management of metastatic, or recurrent cancer, and best supportive care are also discussed. Special topics of interest include treatment and surveillance options for patients with Barrett's esophagus, and suggested strategies to help alleviate the current problems associated with leucovorin shortage.

This is a clinical practice guideline for gastric cancer. The guideline provides an evidence- and consensus-based treatment approach for the management of patients with gastric cancer. Topic areas discussed within the guideline include: staging, principles of pathology, surgery, endoscopic therapies, radiation therapy, combined modality therapy, chemotherapy, and follow-up.

This is a clinical practice guideline for Hodgkin lymphoma. The guideline discusses the clinical management of patients with classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), focusing exclusively on patients from post adolescence through the seventh decade of life who do not have serious intercurrent disease. Areas considered and discussed within the guideline include: staging and prognosis, the role of PET scans, treatment, principles of radiation therapy, and follow-up after completion of treatment.

This is a clinical practice guideline for patients with renal cell carcinoma (RCC). The guideline provides recommendations for the initial evaluation and staging, treatment, and follow-up for adults with various stages of kidney cancer. Topic areas discussed in the guideline include: imaging, surgery, lymph node dissection, targeted therapy, and supportive care.

This is a clinical practice guideline for multiple myeloma. The guideline addresses diagnosis, treatment, and follow-up care. It offers specific recommendations for primary therapy, surveillance and follow-up tests for solitary plasmacytoma, smoldering (asymptomatic) myeloma, active (symptomatic) multiple myeloma, as well as for transplant and non-transplant candidates.

This is a clinical practice guideline for myelodysplastic syndromes (MDS). The guideline provides an update to recommendations on standard approaches to the diagnosis and treatment of MDS in both children and adults. The guideline discusses evaluation and prognostic stratification, Topics of interest include prognostic stratification, evaluation of related anemia and treatment of symptomatic anemia, and supportive care. Molecular abnormalities in MDS and comorbidity indices are also discussed.

This is a clinical practice guideline for Non-Hodgkin's Lymphomas (NHL). The guideline focuses on recommendations for diagnostic workup, treatment, and surveillance strategies for the most common subtypes of NHL, in addition to a general discussion on the classification systems used in NHL and supportive care considerations. The most common NHL subtypes that are covered in the guideline are: Mature B-cell lymphomas, Mature T-cell and NK-cell lymphomas, Post Transplant Lymphoproliferative Disorders (PTLD), and Castleman's Disease.

This clinical practice guideline provides recommendations for evaluation, workup, management, and follow-up of 2 pathologic diagnoses in patients with epithelial occult primary cancer: adenocarcinoma or carcinoma not otherwise specified (NOS), and squamous cell carcinoma (SCC). Diagnostic tests are recommended based on disease location and patient gender. Treatment options for disseminated or localized disease for adenocarcinoma and site-specific SCC are also discussed.

This clinical practice guideline reviews diagnosis and management of adenocarcinomas of the exocrine pancreas. Risk factors and genetic predisposition are discussed, and the guideline provides recommendations on screening, diagnosis and staging, and treatment options including systemic therapy, chemoradiation, and surgical management. Palliative and supportive care are also reviewed. Topics of interest include an overview of biomarkers, and suggestions for management of premalignant tumours of the pancreas.

This is a clinical practice guideline for patients with squamous cell carcinoma (SCC) of the penis. The guideline reviews risk factors and clinical presentation, and provides recommendations for clinical staging, management of primary legions, management of regional lymph nodes, surveillance, and management of metastatic disease. Surgery, radiotherapy, and chemotherapy are reviewed as treatment options.

This is a clinical practice guideline for smoking cessation in patients with cancer. The guideline emphasizes the importance of smoking cessation in all patients with cancer and seeks to establish evidence-based, standard of care recommendations tailored to the unique needs and concerns of patients with cancer. Treatment plans are provided that include recommendations that evaluate the merits of pharmacotherapy, behaviour therapy, and follow-up. The guideline developers acknowledge that smoking and nicotine addiction is a chronic relapsing disorder and as a result, the guideline also provides recommendations around retreatment and the management of relapse.

This is a clinical practice guideline for soft tissue sarcoma. The guideline examines diagnosis, treatment and follow up. Various stages are addressed, as well as a various treatment options and disease progression. Guidance is presented for specific issues (e.g., gastrointestinal stromal tumors).

This is a clinical practice guideline for lung cancer screening in adult patients. The guideline reviews risk factors for lung cancer and provides recommendations on selecting high-risk individuals for screening, guidance on choice of screening modalities with specific review of low dose computed tomography (LDCT), and recommendations on the evaluation and follow-up of nodules found during screening. Additionally, the benefits and risks of screening are discussed.

This is a clinical practice guideline for antiemesis. The guideline examines emesis, types of nausea/vomiting (e.g., chemotherapy induced), antiemetic therapies, and treatment issues associated with antiemetic therapies.

This is a clinical practice guideline for the prevention and treatment of cancer-related infections in neutropenic and immunocompromised non-neutropenic patients with cancer. This guidelines aims to provide an overview of the risk categorization and recommended strategies for prevention of infections in high-risk patient populations, as well as monitoring in patients with signs and/or symptoms of infections. Outcomes of interest include a finding that advances in treatment further emphasize the need for multidisciplinary care.

A clinical practice guideline for the diagnosis and treatment of acute lymphoblastic leukemia in adult and pediatric patients. The guideline examines diagnostic methods, treatment by age group, and special considerations including allogeneic stem cell transplantation and the role of cranial radiation. Outcomes of interest include probability of survival and incidence of hematological relapse.

A clinical practice guideline for adult patients with chronic lymphocytic leukemia. The guideline examines diagnosis, staging, and treatment of newly diagnosed, relapsed, and refractory leukemia. Outcomes of interest include progression-free survival, reduced adverse events, and treatment response.

This is a clinical practice guideline addressing lymphoma in the adult population. The guideline focuses on diagnosis and pathology, staging, and treatment of Non-Hodgkin Lymphomas, Hodgkin Lymphoma, HDCT and hematopoietic stem cell transplantation for lymphoma. Supportive and follow-up care is also addressed. The guideline updates the 2015 guideline of the same title.

This is a clinical practice guideline for patients with, or suspected of having, upper urinary tract urothelial carcinomas (UTUCs). The guideline reviews diagnostic assessment, staging, treatment, and follow-up. Treatment recommendations are provided based on whether the disease is localized or advanced and include radical nephroureterectomy, conservative surgery, adjuvant topical agents, chemotherapy, and radiotherapy. Outcomes of interest include risk factors, sensitivity and specificity of diagnostic tests, survival (recurrence-free, disease-free, and overall), disease progression, morbidity, and mortality.

A clinical practice guideline for patients with primary cutaneous melanoma. The guideline examines diagnosis, treatment, and follow-up including preventive excision and body mapping. Outcomes of interest include melanoma-specific survival and morbidity.

This guideline outlines the screening, diagnosis, treatment, and follow-up of human papillomavirus related cancers. The guideline examines appropriate vaccination strategies, screening (including care controversies), and treatment including chemotherapy and surgical options. Outcomes of interest include fertility sparing and reduction of unnecessary Pap testing. Provincial resources are provided.

This clinical practice guideline reviews workup, staging, and treatment for both noninvasive and invasive breast cancer. Special considerations include phyllodes tumor, Paget's disease, breast cancer during pregnancy, and inflammatory breast cancer. Treatment recommendations for invasive cancer are stratified by tumor receptor status and stage. Fertility and birth control is also discussed.

This is a clinical practice guideline for patients with cervical cancer including squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma of the cervix. The guideline discusses diagnosis and workup, principles of staging and surgery, primary treatment, adjuvant treatment, surveillance, and therapy for relapse. Special topics of consideration include incidental cervical cancer, radiation therapy, and cervical cancer and pregnancy.

This is a clinical practice guideline for patients with colon cancer or adenocarcinomas of the small bowel and appendix. The guideline reviews staging, pathology, clinical presentation and treatment of nonmetastatic disease, management of metastatic disease, post-treatment surveillance, and survivorship. The role of vitamin D in colorectal cancer is also discussed.

This clinical practice guideline reviews diagnostic assessment and management of prostate cancer. The guideline discusses risk stratification, molecular testing, and imaging for clinical assessment and staging workup. Management options reviewed include observation, active surveillance, radical prostatectomy, radiation therapy, androgen deprivation therapy, chemotherapy, and immunotherapy, with treatment recommendations stratified by risk. Outcomes of interest include survival and adverse effects of treatment.

This is a clinical practice guideline for small cell lung cancer and lung neuroendocrine tumours. Diagnosis, staging, prognostic factors, treatment and surveillance are reviewed. Treatment options include chemotherapy, with special topics of discussion including elderly patients and second- and third-line therapies, radiotherapy (thoracic radiotherapy, prophylactic cranial irradiation, and palliative radiotherapy), and surgery. Outcomes of interest include survival (disease free, overall, progression-free), response rates, and treatment toxicity.

This is a clinical practice guideline for adult patients with non-small cell lung cancer. The guideline provides updated recommendations around prevention and screening, evaluation and staging, treatment, and follow up care. Areas of focus are discussed with recognition that much progress has been made in regards to screening, minimally invasive techniques for diagnosis and treatment, advances in radiation therapy (RT) including stereotactic ablative radiotherapy (SABR), and targeted therapies.

These clinical practice guidelines for survivorship provide screening, evaluation, and treatment recommendations for common consequences of cancer and cancer treatment to aid health care professionals who work with survivors of adult-onset cancer in the post-treatment period, including those in specialty cancer survivor clinics and primary care practices. The guidelines focus on the vast and persistent impact both the diagnosis and treatment of cancer can have on the adult survivor’s health, physical and mental states, health behaviors, professional and personal identity, sexuality, and financial standing.

This guideline applies to patients with ductal carcinoma in situ (DCIS) treated with whole-breast radiation therapy (WBRT). The primary question addressed in this guideline is "what margin width minimizes the risk of ipsi-lateral breast tumor recurrence (IBTR) in patients with DCIS receiving breast-conserving surgery?" The guideline developed from a consensus panel is intended to assist treating physicians and patients in the clinical decision-making process based on the best available evidence.

This is a clinical practice guideline provides evidence-based recommendations to oncologists and others on potentially curative therapy for patients with localized pancreatic cancer. Key recommendations are guided by questions including: what initial assessment is recommended before initiating any therapy for potentially curable pancreatic cancer; what is the appropriate adjuvant regimen for patients with pancreatic cancer who have undergone a resection of their primary tumor; and when should palliative care services be initiated for people with pancreatic cancer that is potentially curable by surgery.

This clinical practice guideline provides evidence-based recommendations to oncologists and others for treatment of patients with locally advanced, unresectable pancreatic cancer (LAPC). The guideline addresses a number of key clinical questions including: what initial assessment is recommended before initiating therapy for LAPC; what is the appropriate initial treatment approach for people diagnosed with LAPC; and for people with LAPC, what are the recommended strategies for relief of pain and symptom burden.

This is a clinical practice guideline for the treatment of patients with metastatic pancreatic cancer. This clinical practice guideline addresses six overarching clinical questions: After a histopathologic confirmation of pancreatic adenocarcinoma diagnosis, what initial assessment is recommended before initiating any therapy for metastatic pancreatic cancer? What is the appropriate first-line treatment of patients with metastatic pancreatic cancer? What is the appropriate therapy for patients with metastatic pancreatic cancer who experience either disease progression or intolerable toxicity with prior regimens for metastatic pancreatic cancer? When should the concept of palliative care be introduced? For patients with metastatic pancreatic cancer, what are the recommended strategies for relief of pain and symptoms? What is the recommended frequency of follow-up care/surveillance for patients with metastatic pancreatic cancer?

This clinical practice guideline provides recommendations on the investigation, treatment, and follow-up care of patients aged 16 years and older with cancer of the upper aerodigestive tract. HPV-related disease and less common upper aerodigestive tract cancers including carcinoma of the nasopharynx or paranasal sinuses, unknown primary of presumed upper aerodigestive tract origin, and mucosal melanoma, are also reviewed. Additionally, recommendations are provided on optimizing rehabilitation and function. Outcomes of interest include prevalence, predictive value, sensitivity, specificity, local control, survival (overall, progression-free), treatment-related morbidity and mortality, and resource use, among others.

This is a clinical practice guideline for stage I breast cancer, and focuses specifically on the initial workup and surveillance for local recurrence and distant metastases in asymptomatic women. Recommendations are made with different variants in mind, including newly diagnosed cases, surveillance, and ruling out brain metastases, liver metastases, and thoracic metastases. The guideline also considers the appropriateness of different imaging procedures to detect or rule out metastasis.

This is a clinical practice guideline for the staging of testicular malignancy. Recommendations are made with consideration of the following variant: staging testis tumour, diagnosed by orchiectomy. The guideline also discusses tumour markers and provides an overview of imaging modalities.

This clinical practice guideline provides recommendations for follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer. The guideline addresses the following questions which include: what evaluations (e.g., colonoscopy, computed tomography [CT], carcinoembryonic antigen [CEA], liver function, complete blood count [CBC], chest x-ray, history, physical exam) should be performed for surveillance for recurrence of cancer? What is a reasonable frequency of these evaluations for surveillance? Which symptoms and/or signs potentially signify a recurrence of CRC and warrant investigation?

This is a clinical practice guideline for adult patients with thyroid nodules and differentiated thyroid cancer (DTC). The guideline provides recommendations on initial management of thyroid cancer including screening, staging, risk assessment, surgical management, radioiodine remnant ablation and therapy, and thyrotropin suppression therapy using levothyroxine, as well as long-term management including surveillance techniques, management of recurrent and metastatic disease, and consideration for clinical trials and targeted therapy. The evaluation and diagnostic approach for thyroid nodules is also discussed, including a review of indications for fine-needle aspiration biopsy and interpretation of results, as well as use of molecular markers and management of benign thyroid nodules. Outcomes of interest include survival, recurrence, sensitivity and specificity.

This is a clinical practice guideline for teleoncology models of care. Teleoncology seeks to offer solutions to some of the access issues faced by patients and health professionals from regional, rural and remote communities around the world. The focus of the guideline is shaped by a number of clinical questions that include: what teleoncology models of care are available to health services in Australia and overseas; what models of care for teleoncology are available to nursing services; what models of care for teleoncology are available to allied health services; is teleoncology as effective as standard oncology care for the screening of cancer; is teleoncology as effective as standard oncology care for the diagnosis of cancer; is teleoncology as effective as standard oncology care for the treatment of cancer; and is teleoncology as effective as standard oncology care for the palliative care of cancer patients.

This is a clinical practice guideline for male patients diagnosed with or suspected of having prostate cancer. The guideline reviews classification and staging, diagnostic evaluation, disease management, and follow-up care. Side effects of local treatment and health-related quality of life in prostate cancer survivors are also discussed. Outcomes of interest include overall survival, cancer-specific survival, development of metastatic disease, sensitivity and specificity of diagnostic procedures, and side effects of treatment.

This guideline is for adult patients over 16 years of age with suspected, newly diagnosed, or relapsed myeloma. The guideline provides recommendations on laboratory and imaging investigations, management of newly diagnosed myeloma, managing acute renal disease caused by myeloma, preventing and managing complications, disease monitoring, and managing relapsed myeloma. Recommendations are also provided on service organization. Outcomes of interest include time to biochemical and/or clinical progression, overall survival, adverse events, quality of life and resource use.